

Advances in oligonucleotide drug delivery

Nature Reviews Drug Discovery

19, 673-694

DOI: [10.1038/s41573-020-0075-7](https://doi.org/10.1038/s41573-020-0075-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nanomaterials for Therapeutic RNA Delivery. <i>Matter</i> , 2020, 3, 1948-1975.	5.0	67
2	The Therapeutic Potential of MicroRNAs in Cancer: Illusion or Opportunity?. <i>Pharmaceuticals</i> , 2020, 13, 438.	1.7	13
3	RNA Secondary Structure as a First Step for Rational Design of the Oligonucleotides towards Inhibition of Influenza A Virus Replication. <i>Pathogens</i> , 2020, 9, 925.	1.2	17
4	Synthesis and properties of GuNA purine/pyrimidine nucleosides and oligonucleotides. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 9461-9472.	1.5	10
5	Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases. <i>Brain Sciences</i> , 2020, 10, 633.	1.1	3
6	RNA-Peptide Conjugation through an Efficient Covalent Bond Formation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 8920.	1.3	3
7	Supramolecular Architectures of Nucleic Acid/Peptide Hybrids. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9458.	1.8	10
8	Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer. <i>Cancers</i> , 2020, 12, 3695.	1.7	11
9	Pleiotropic Effects of Bacterial Small Alarmone Synthetases: Underscoring the Dual-Domain Small Alarmone Synthetases in <i>Mycobacterium smegmatis</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 594024.	1.5	6
10	Nucleic Acid-Based Technologies Targeting Coronaviruses. <i>Trends in Biochemical Sciences</i> , 2021, 46, 351-365.	3.7	35
11	Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. <i>Biochemical Pharmacology</i> , 2021, 184, 114364.	2.0	54
12	High-resolution visualization and quantification of nucleic acid-based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS). <i>Nucleic Acids Research</i> , 2021, 49, 1-14.	6.5	51
13	Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF- α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 601155.	2.0	11
14	Recent Advances in the Development of Exogenous dsRNA for the Induction of RNA Interference in Cancer Therapy. <i>Molecules</i> , 2021, 26, 701.	1.7	0
15	Synthesis and fundamental studies of a photoresponsive oligonucleotide-upconverting nanoparticle covalent conjugate. <i>Materials Chemistry Frontiers</i> , 2021, 5, 4690-4699.	3.2	1
16	In vivo silencing of amphiregulin by a novel effective Self-Assembled-Micelle inhibitory RNA ameliorates renal fibrosis via inhibition of EGFR signals. <i>Scientific Reports</i> , 2021, 11, 2191.	1.6	12
17	Conjugation Approaches for Peptide-Mediated Delivery of Oligonucleotides Therapeutics. <i>Australian Journal of Chemistry</i> , 2022, 75, 24-33.	0.5	6
18	Expanding the Scope of the Cleavable N-(Methoxy)oxazolidine Linker for the Synthesis of Oligonucleotide Conjugates. <i>Molecules</i> , 2021, 26, 490.	1.7	4

#	ARTICLE	IF	CITATIONS
19	DNA-polymer conjugates via the graft-through polymerisation of native DNA in water. <i>Chemical Communications</i> , 2021, 57, 5466-5469.	2.2	6
20	Recent progress in non-native nucleic acid modifications. <i>Chemical Society Reviews</i> , 2021, 50, 5126-5164.	18.7	155
21	Novel Lipid-Oligonucleotide Conjugates Containing Long-Chain Sulfonyl Phosphoramidate Groups: Synthesis and Biological Properties. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1174.	1.3	12
22	Chemical synthesis of stimuli-responsive guide RNA for conditional control of CRISPR-Cas9 gene editing. <i>Chemical Science</i> , 2021, 12, 9934-9945.	3.7	13
23	Inhibition of off-target cleavage by RNase H using an artificial cationic oligosaccharide. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 6865-6870.	1.5	3
24	Lumasiran: First Approval. <i>Drugs</i> , 2021, 81, 277-282.	4.9	168
25	Prioritising breast cancer theranostics: A current medical longing in oncology. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100465.	0.7	3
26	Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery. <i>Biochemistry</i> , 2021, 60, 966-990.	1.2	18
27	ADAR-Mediated RNA Editing and Its Therapeutic Potentials. <i>RNA Technologies</i> , 2021, , 471-503.	0.2	3
28	The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 291-306.	1.5	67
29	Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. <i>Journal of Clinical Medicine</i> , 2021, 10, 838.	1.0	46
30	A specific tRNA half, 5'-tRNA-His-GTC, responds to hypoxia via the HIF1 α /ANG axis and promotes colorectal cancer progression by regulating LATS2. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 67.	3.5	59
31	Trace-Level Determination of Acrylonitrile Generated in the Manufacturing Process of Oligonucleotides by Static Headspace Gas Chromatography with an Electron Impact(+) Mass Detector. <i>Organic Process Research and Development</i> , 2021, 25, 318-326.	1.3	4
32	Dissecting the impact of target-binding kinetics of protein binders on tumor localization. <i>IScience</i> , 2021, 24, 102104.	1.9	3
33	Efficient antisense inhibition reveals microRNA-155 to restrain a late-myeloid inflammatory programme in primary human phagocytes. <i>RNA Biology</i> , 2021, 18, 604-618.	1.5	5
34	U7 snRNA: A tool for gene therapy. <i>Journal of Gene Medicine</i> , 2021, 23, e3321.	1.4	21
35	Aberrant Expression of microRNA Clusters in Head and Neck Cancer Development and Progression: Current and Future Translational Impacts. <i>Pharmaceuticals</i> , 2021, 14, 194.	1.7	3
36	Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication. <i>Molecules</i> , 2021, 26, 956.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Synthesis and properties of oligonucleotides bearing thymidine derivatives with 1,6-dioxaspiro[4.5]decane skeleton. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 31, 115966.	1.4	3
38	Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2210.	1.8	27
39	Tailor-made oligonucleotide-loaded lipid-polymer nanosystems designed for bone gene therapy. <i>Drug Delivery and Translational Research</i> , 2021, 11, 598-607.	3.0	9
40	Oligonucleotides Containing 1-Aminomethyl or 1-Mercaptomethyl-2-deoxy- β -D-ribofuranoses: Synthesis, Purification, Characterization, and Conjugation with Fluorophores and Lipids. <i>Bioconjugate Chemistry</i> , 2021, 32, 350-366.	1.8	5
41	Long Non-Coding RNAs as Key Modulators of Pancreatic β -Cell Mass and Function. <i>Frontiers in Endocrinology</i> , 2020, 11, 610213.	1.5	15
42	What makes a good antibody-drug conjugate?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 841-847.	1.4	22
43	Non-Coding RNAs Steering the Senescence-Related Progress, Properties, and Application of Mesenchymal Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 650431.	1.8	13
44	Local Protein Translation and RNA Processing of Synaptic Proteins in Autism Spectrum Disorder. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2811.	1.8	16
45	Oligonucleotide-Based Therapies for Renal Diseases. <i>Biomedicines</i> , 2021, 9, 303.	1.4	10
46	Dopamine-Grafted Hyaluronic Acid Coated Hyperbranched Poly(β -Amino Esters)/DNA Nano-Complexes for Enhanced Gene Delivery and Biosafety. <i>Crystals</i> , 2021, 11, 347.	1.0	8
47	Electrospun Nanofibrous Scaffolds: Review of Current Progress in the Properties and Manufacturing Process, and Possible Applications for COVID-19. <i>Polymers</i> , 2021, 13, 916.	2.0	14
48	Recent Advances in Oligonucleotide Therapeutics in Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3295.	1.8	96
49	Modular Synthesis of Trifunctional Peptide-oligonucleotide Conjugates via Native Chemical Ligation. <i>Frontiers in Chemistry</i> , 2021, 9, 627329.	1.8	9
50	CaMKII δ Splice Variants in the Healthy and Diseased Heart. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 644630.	1.8	13
51	Designing in vivo active DNAzymes. <i>Nature Chemistry</i> , 2021, 13, 299-301.	6.6	11
52	Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3526.	1.8	2
53	Recent Advances in the Synthesis of High Boron-Loaded Nucleic Acids for BNCT. <i>Frontiers in Chemistry</i> , 2021, 9, 619052.	1.8	19
55	RNA-based therapies: A cog in the wheel of lung cancer defense. <i>Molecular Cancer</i> , 2021, 20, 54.	7.9	53

#	ARTICLE	IF	CITATIONS
56	Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against <i>Sporothrix schenckii</i> . <i>International Journal of Molecular Sciences</i> , 2021, 22, 3470.	1.8	5
58	Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System. <i>Molecular Pharmaceutics</i> , 2021, 18, 1491-1506.	2.3	32
59	General Method for Post-Synthetic Modification of Oligonucleotides Based on Oxidative Amination of 4-Thio-2-deoxyuridine. <i>Bioconjugate Chemistry</i> , 2021, 32, 721-728.	1.8	4
60	Candidates for Intra-Articular Administration Therapeutics and Therapies of Osteoarthritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3594.	1.8	11
61	RNA therapeutics for cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 256-263.	0.8	11
62	The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1976.	1.7	9
63	Nucleic Acid-Based Therapeutics in Orphan Neurological Disorders: Recent Developments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 643681.	1.6	10
64	In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. <i>Cell</i> , 2021, 184, 1865-1883.e20.	13.5	153
65	Cytocompatibility, membrane disruption, and siRNA delivery using environmentally responsive cationic nanogels. <i>Journal of Controlled Release</i> , 2021, 332, 608-619.	4.8	13
66	Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing. <i>Nucleic Acids Research</i> , 2021, 49, 4864-4876.	6.5	8
67	RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays. <i>Molecules</i> , 2021, 26, 2263.	1.7	21
68	Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges. <i>Molecular Therapy</i> , 2022, 30, 47-53.	3.7	13
69	In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells. <i>Molecules</i> , 2021, 26, 2610.	1.7	8
70	Beyond ribose and phosphate: Selected nucleic acid modifications for structure-function investigations and therapeutic applications. <i>Beilstein Journal of Organic Chemistry</i> , 2021, 17, 908-931.	1.3	20
71	Delivery of oligonucleotide-based therapeutics: challenges and opportunities. <i>EMBO Molecular Medicine</i> , 2021, 13, e13243.	3.3	181
72	A Versatile Solid-Phase Approach to the Synthesis of Oligonucleotide Conjugates with Biodegradable Hydrazone Linker. <i>Molecules</i> , 2021, 26, 2119.	1.7	5
73	The importance of genetic testing for dystonia patients and translational research. <i>Journal of Neural Transmission</i> , 2021, 128, 473-481.	1.4	6
74	Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer. <i>Bioengineering</i> , 2021, 8, 44.	1.6	11

#	ARTICLE	IF	CITATIONS
75	Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 571076.	1.1	4
76	Denaturing and Native Mass Spectrometric Analytics for Biotherapeutic Drug Discovery Research: Historical, Current, and Future Personal Perspectives. <i>Journal of the American Society for Mass Spectrometry</i> , 2021, 32, 1861-1885.	1.2	27
77	Reinforced electrospun nanofiber composites for drug delivery applications. <i>Journal of Biomedical Materials Research - Part A</i> , 2021, 109, 2036-2064.	2.1	21
78	The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. <i>Biomedicines</i> , 2021, 9, 433.	1.4	79
79	Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. <i>Thrombosis Research</i> , 2021, 200, 64-71.	0.8	11
80	Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. <i>Pharmaceutics</i> , 2021, 13, 544.	2.0	20
81	² Fluoro-arabinonucleic Acid (FANA): A Versatile Tool for Probing Biomolecular Interactions. <i>Accounts of Chemical Research</i> , 2021, 54, 2287-2297.	7.6	27
82	Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates. <i>Drug Discovery Today</i> , 2021, 26, 2244-2258.	3.2	17
83	Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120392.	2.6	29
84	Nanoparticle Delivered Anti-miR-141-3p for Stroke Therapy. <i>Cells</i> , 2021, 10, 1011.	1.8	22
85	Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4751.	1.8	7
86	Impurity profiling of siRNA by two-dimensional liquid chromatography-mass spectrometry with quinine carbamate anion-exchanger and ion-pair reversed-phase chromatography. <i>Journal of Chromatography A</i> , 2021, 1643, 462065.	1.8	18
87	Post-Transcriptional Regulation in Skeletal Muscle Development, Repair, and Disease. <i>Trends in Molecular Medicine</i> , 2021, 27, 469-481.	3.5	20
88	Recent Advances of DNA Hydrogels in Biomedical Applications. <i>Journal of Analysis and Testing</i> , 2021, 5, 155-164.	2.5	9
90	Chemical Manipulation of the Endosome Trafficking Machinery: Implications for Oligonucleotide Delivery. <i>Biomedicines</i> , 2021, 9, 512.	1.4	14
91	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine—Specific Cancer Targeting with Undetectable Toxicity. <i>Chemical Reviews</i> , 2021, 121, 7398-7467.	23.0	45
92	Beyond small molecules: targeting G-quadruplex structures with oligonucleotides and their analogues. <i>Nucleic Acids Research</i> , 2021, 49, 6638-6659.	6.5	35
93	Anti-tumour drugs of marine origin currently at various stages of clinical trials (review). <i>Regulatory Mechanisms in Biosystems</i> , 2021, 12, 265-280.	0.5	3

#	ARTICLE	IF	CITATIONS
95	Mechanisms of viral persistence in the brain and therapeutic approaches. <i>FEBS Journal</i> , 2022, 289, 2145-2161.	2.2	12
96	The current landscape of nucleic acid therapeutics. <i>Nature Nanotechnology</i> , 2021, 16, 630-643.	15.6	578
97	Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery. <i>Biomedicines</i> , 2021, 9, 583.	1.4	31
98	Recent advances in HER2-targeted delivery for cancer therapy. <i>Drug Discovery Today</i> , 2021, 26, 1319-1329.	3.2	29
99	Synthesis and Biological Evaluation of an iso DGR α -Paclitaxel Conjugate Containing a Cell α -Penetrating Peptide to Promote Cellular Uptake. <i>European Journal of Organic Chemistry</i> , 2021, 2021, 2383-2387.	1.2	1
100	Antisense Tissue Factor Oligodeoxynucleotides Protected Diethyl Nitrosamine/Carbon Tetrachloride-Induced Liver Fibrosis Through Toll Like Receptor4-Tissue Factor-Protease Activated Receptor1 Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 676608.	1.6	1
101	Synthesis and Properties of 4 α -ThioLNA/BNA. <i>Organic Letters</i> , 2021, 23, 4062-4066.	2.4	6
102	Recent advances in liposome formulations for breast cancer therapeutics. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5225-5243.	2.4	41
103	Spinocerebellar ataxia clinical trials: opportunities and challenges. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1543-1556.	1.7	33
104	Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers. <i>Pharmaceutics</i> , 2021, 13, 697.	2.0	8
105	microRNA-based diagnostic and therapeutic applications in cancer medicine. <i>Wiley Interdisciplinary Reviews RNA</i> , 2021, 12, e1662.	3.2	55
106	The 2-Aminopyridine Nucleobase Improves Triple-Helical Recognition of RNA and DNA When Used Instead of Pseudoisocytosine in Peptide Nucleic Acids. <i>Biochemistry</i> , 2021, 60, 1919-1925.	1.2	18
108	Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	40
109	Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 194.	3.5	17
110	The Role of microRNAs and Long Non-Coding RNAs in the Regulation of the Immune Response to Mycobacterium tuberculosis Infection. <i>Frontiers in Immunology</i> , 2021, 12, 687962.	2.2	30
111	Reactive oxygen species-responsive nanoplatforms for nucleic acid-based gene therapy of cancer and inflammatory diseases. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 042015.	1.7	6
112	Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e153-e165.	1.8	12
113	Bioinert, Stealth or Interactive: How Surface Chemistry of Nanocarriers Determines Their Fate In Vivo. <i>Advanced Functional Materials</i> , 2021, 31, 2103347.	7.8	41

#	ARTICLE	IF	CITATIONS
114	RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics. Annual Review of Chemical and Biomolecular Engineering, 2021, 12, 263-286.	3.3	8
115	The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure. Epilepsy and Behavior, 2021, 119, 107975.	0.9	11
116	Systematically Studying the Effect of Small Molecules Interacting with RNA in Cellular and Preclinical Models. ACS Chemical Biology, 2021, 16, 1111-1127.	1.6	10
117	The role of ligand-binding assay and LC-MS in the bioanalysis of complex protein and oligonucleotide therapeutics. Bioanalysis, 2021, 13, 931-954.	0.6	9
118	Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI. Journal of the American Society of Nephrology: JASN, 2021, 32, 2467-2483.	3.0	50
119	Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors. Pharmaceuticals, 2021, 14, 554.	1.7	20
120	Spherical Nucleic Acids for Near-Infrared Light-Responsive Self-Delivery of Small-Interfering RNA and Antisense Oligonucleotide. ACS Nano, 2021, 15, 11929-11939.	7.3	54
121	The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond. Cancers, 2021, 13, 3115.	1.7	6
122	Application of Magnetic Nanoparticles Coated with Crosslinked Zwitterionic Poly(ionic liquid)s for the Extraction of Oligonucleotides. Materials, 2021, 14, 3146.	1.3	6
124	Innovations in Disease State Responsive Soft Materials for Targeting Extracellular Stimuli Associated with Cancer, Cardiovascular Disease, Diabetes, and Beyond. Advanced Materials, 2021, 33, e2007504.	11.1	23
125	Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases. Journal of Neuromuscular Diseases, 2021, 8, 869-884.	1.1	19
126	An Investigation into the Potential of Targeting Escherichia coli rne mRNA with Locked Nucleic Acid (LNA) Gappers as an Antibacterial Strategy. Molecules, 2021, 26, 3414.	1.7	0
127	Therapeutic targeting of RNA-binding protein by RNA-PROTAC. Molecular Therapy, 2021, 29, 1940-1942.	3.7	15
128	Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects. Advanced Drug Delivery Reviews, 2021, 173, 427-438.	6.6	38
129	Wound Healing: From Passive to Smart Dressings. Advanced Healthcare Materials, 2021, 10, e2100477.	3.9	264
130	Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy. Advanced Drug Delivery Reviews, 2021, 174, 1-29.	6.6	40
132	Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure. Frontiers in Immunology, 2021, 12, 708806.	2.2	11
133	Effective silencing of miR-126 after ischemic stroke by means of intravenous α -tocopherol-conjugated heteroduplex oligonucleotide in mice. Scientific Reports, 2021, 11, 14237.	1.6	5

#	ARTICLE	IF	CITATIONS
134	Chemical approaches to discover the full potential of peptide nucleic acids in biomedical applications. <i>Beilstein Journal of Organic Chemistry</i> , 2021, 17, 1641-1688.	1.3	32
135	Integration of chemically modified nucleotides with DNA strand displacement reactions for applications in living systems. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1743.	3.3	7
136	Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment. <i>Biomedicines</i> , 2021, 9, 795.	1.4	5
137	Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	6
138	Avoiding High Pressure Problem for Modified RNA Attached Polystyrene Support by Pre Swelling Using Toluene in the Oligonucleotide Synthesis. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 1296.	1.0	2
139	Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review. <i>Frontiers in Oncology</i> , 2021, 11, 712786.	1.3	29
140	Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 576-612.	6.6	36
141	Factor XII(a) inhibitors: a review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 1155-1176.	2.4	20
142	Cationic oligonucleotide derivatives and conjugates: A favorable approach for enhanced DNA and RNA targeting oligonucleotides. <i>Beilstein Journal of Organic Chemistry</i> , 2021, 17, 1828-1848.	1.3	5
143	Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects. <i>International Immunopharmacology</i> , 2021, 96, 107761.	1.7	5
144	Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. <i>Small Methods</i> , 2021, 5, 2100402.	4.6	45
145	Oligonucleotide Therapies in the Treatment of Arthritis: A Narrative Review. <i>Biomedicines</i> , 2021, 9, 902.	1.4	9
146	From Junk to Function: LncRNAs in CNS Health and Disease. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 714768.	1.4	27
147	Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. <i>Pharmaceutics</i> , 2021, 13, 1106.	2.0	7
148	A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. <i>Annals of the New York Academy of Sciences</i> , 2021, 1502, 5-13.	1.8	7
149	Lipids and Lipid Derivatives for RNA Delivery. <i>Chemical Reviews</i> , 2021, 121, 12181-12277.	23.0	227
150	Therapeutics Development for Alagille Syndrome. <i>Frontiers in Pharmacology</i> , 2021, 12, 704586.	1.6	7
151	Splice-switching as cancer therapy. <i>Current Opinion in Pharmacology</i> , 2021, 59, 140-148.	1.7	10

#	ARTICLE	IF	CITATIONS
152	Selectivity limits of and opportunities for ion pair chromatographic separation of oligonucleotides. <i>Journal of Chromatography A</i> , 2021, 1651, 462269.	1.8	21
153	Effective Osteogenic Priming of Mesenchymal Stem Cells through LNA-ASOs-Mediated Sfrp1 Gene Silencing. <i>Pharmaceutics</i> , 2021, 13, 1277.	2.0	4
154	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
155	Medical Hegemony and Healthcare: Centrality in Healthcare. , 0, , .		1
156	Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 600-620.	5.7	106
157	Expanding the chemical functionality of DNA nanomaterials generated by rolling circle amplification. <i>Nucleic Acids Research</i> , 2021, 49, 9042-9052.	6.5	18
158	Pterostilbene Increases LDL Metabolism in HL-1 Cardiomyocytes by Modulating the PCSK9/HNF1 β /SREBP2/LDLR Signaling Cascade, Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression. <i>Antioxidants</i> , 2021, 10, 1280.	2.2	8
159	Optimizing Efficient RNAi-Mediated Control of Hemipteran Pests (Psyllids, Leafhoppers, Whitefly): Modified Pyrimidines in dsRNA Triggers. <i>Plants</i> , 2021, 10, 1782.	1.6	11
160	Supramolecular "Click Chemistry" for Targeting in the Body. <i>Bioconjugate Chemistry</i> , 2021, 32, 1935-1946.	1.8	20
161	Synthesis and validation of DOPY: A new gemini dioleilylpyridinium based amphiphile for nucleic acid transfection. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 279-292.	2.0	7
162	A mechanistic review of the anticancer potential of hesperidin, a natural flavonoid from citrus fruits. <i>Nutrition Research</i> , 2021, 92, 21-31.	1.3	56
163	Transcriptome-Wide Off-Target Effects of Steric-Blocking Oligonucleotides. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 392-403.	2.0	42
164	Emerging innate biological properties of nano-drug delivery systems: A focus on PAMAM dendrimers and their clinical potential. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113908.	6.6	61
165	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. <i>Small</i> , 2021, 17, e2103025.	5.2	29
166	Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments. <i>Journal of Chromatography A</i> , 2021, 1651, 462283.	1.8	12
167	Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, .	1.8	12
168	Precision Spherical Nucleic Acids Enable Sensitive FEN1 Imaging and Controllable Drug Delivery for Cancer-Specific Therapy. <i>Analytical Chemistry</i> , 2021, 93, 11275-11283.	3.2	34
169	Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**. <i>Angewandte Chemie</i> , 2021, 133, 21830-21835.	1.6	3

#	ARTICLE	IF	CITATIONS
170	Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 21662-21667.	7.2	21
171	High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8378.	1.8	9
172	MicroRNA as an Important Target for Anticancer Drug Development. <i>Frontiers in Pharmacology</i> , 2021, 12, 736323.	1.6	56
174	Alpha1-antitrypsin deficiency: New therapies on the horizon. <i>Current Opinion in Pharmacology</i> , 2021, 59, 149-156.	1.7	20
175	Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113809.	6.6	30
176	Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. <i>Advanced Science</i> , 2021, 8, e2102555.	5.6	56
177	Bacterial Nosocomial Infections: Multidrug Resistance as a Trigger for the Development of Novel Antimicrobials. <i>Antibiotics</i> , 2021, 10, 942.	1.5	8
178	Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3950-3965.	5.7	10
179	Systematic review and network analysis of microRNAs involved in cardioprotection against myocardial ischemia/reperfusion injury and infarction: Involvement of redox signalling. <i>Free Radical Biology and Medicine</i> , 2021, 172, 237-251.	1.3	23
180	Liposome-based delivery of biological drugs. <i>Chinese Chemical Letters</i> , 2022, 33, 587-596.	4.8	79
181	miR-204: Molecular Regulation and Role in Cardiovascular and Renal Diseases. <i>Hypertension</i> , 2021, 78, 270-281.	1.3	13
182	Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease. <i>Journal of Molecular Biology</i> , 2022, 434, 167220.	2.0	13
183	Nucleic Acids Based Polyelectrolyte Complexes: Their Complexation Mechanism, Morphology, and Stability. <i>Chemistry of Materials</i> , 2021, 33, 7923-7943.	3.2	20
184	Sequence-Defined Synthetic Polymers for New-Generation Functional Biomaterials. , 2021, 3, 1339-1356.		28
185	The Expanding Role of Alternative Splicing in Vascular Smooth Muscle Cell Plasticity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10213.	1.8	7
186	Towards the enzymatic synthesis of phosphorothioate containing LNA oligonucleotides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 48, 128242.	1.0	15
187	Recent developments in the characterization of nucleic acid hybridization kinetics. <i>Current Opinion in Biomedical Engineering</i> , 2021, 19, 100305.	1.8	2
188	Key considerations in formulation development for gene therapy products. <i>Drug Discovery Today</i> , 2022, 27, 292-303.	3.2	9

#	ARTICLE	IF	CITATIONS
189	Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 761-776.	2.7	28
190	iPSC toolbox for understanding and repairing disrupted brain circuits in autism. <i>Molecular Psychiatry</i> , 2021, , .	4.1	3
191	Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 734720.	1.8	75
192	Simultaneous quantitation of inorganic ions in oligonucleotides using mixed-mode liquid chromatography coupled with a charged aerosol detector. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 204, 114244.	1.4	5
193	Chemistry of Peptide-Oligonucleotide Conjugates: A Review. <i>Molecules</i> , 2021, 26, 5420.	1.7	40
194	Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10Åkb C-to-T splicing mutation. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 865-875.	0.3	30
195	A Bioreductive Protecting Group for RNA Synthesis. <i>Current Protocols</i> , 2021, 1, e240.	1.3	0
196	Nucleic acid delivery and nanoparticle design for COVID vaccines. <i>MRS Bulletin</i> , 2021, 46, 832-839.	1.7	12
197	Safety Testing of an Antisense Oligonucleotide Intended for Pediatric Indications in the Juvenile GÅtttingen Minipig, including an Evaluation of the Ontogeny of Key Nucleases. <i>Pharmaceutics</i> , 2021, 13, 1442.	2.0	4
198	Electroanalysis at a Single Giant Vesicle Generating Enzymatically a Reactive Oxygen Species. <i>Analytical Chemistry</i> , 2021, 93, 13143-13151.	3.2	5
199	RNA Silencing in the Management of Dyslipidemias. <i>Current Atherosclerosis Reports</i> , 2021, 23, 69.	2.0	19
200	Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. <i>ACS Nano</i> , 2021, 15, 13993-14021.	7.3	74
201	Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation. <i>Pharmaceutics</i> , 2021, 13, 1520.	2.0	4
202	Synthesis and duplex-forming ability of oligonucleotides modified with 4â€²-C,5â€²-C-methylene-bridged nucleic acid (4â€²,5â€²-BNA). <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116359.	1.4	2
203	Synthesis and Properties of Oligonucleotides Containing 2â€²â€²O</i>,4â€²â€²C</i>â€²Ethyleneâ€²Bridged 5â€²Methyluridine with Exocyclic Methylene and Methyl Groups in the Bridge. <i>European Journal of Organic Chemistry</i> , 2021, 2021, 4993-5002.	1.2	3
204	Nucleic acid delivery for therapeutic applications. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113834.	6.6	122
205	PolyPurine Reverse Hoogsteen Hairpins Work as RNA Species for Gene Silencing. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10025.	1.8	3
206	CHOP-ASO Ameliorates Glomerular and Tubular Damage on Top of ACE Inhibition in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3066-3079.	3.0	14

#	ARTICLE	IF	CITATIONS
207	A review study on the modulation of SIRT1 expression by miRNAs in aging and age-associated diseases. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 52-61.	3.6	23
208	Programmable technologies to manipulate gene expression at the RNA level. <i>Current Opinion in Chemical Biology</i> , 2021, 64, 27-37.	2.8	2
209	Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. , 2021, 227, 107873.		17
210	Delivery of therapeutic oligonucleotides in nanoscale. <i>Bioactive Materials</i> , 2022, 7, 292-323.	8.6	29
211	The controlled release of active substance from one-dimensional inorganic nanocarrier for the stability enhancement of lithium batteries. <i>Chemical Engineering Journal</i> , 2022, 427, 131748.	6.6	6
212	Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology <i>in vivo</i> . <i>Nucleic Acids Research</i> , 2022, 50, 1221-1240.	6.5	29
213	Therapeutic reversal of Huntington's disease by <i>in vivo</i> self-assembled siRNAs. <i>Brain</i> , 2021, 144, 3421-3435.	3.7	36
214	Challenges and Opportunities of Nanomedicines in Clinical Translation. <i>BIO Integration</i> , 2021, 2, .	0.9	99
215	Zn ²⁺ -Dependent peptide nucleic acid-based artificial ribonucleases with unprecedented efficiency and specificity. <i>Chemical Communications</i> , 2021, 57, 10911-10914.	2.2	7
216	Gene and epigenetic editing in the treatment of primary ciliopathies. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 182, 353-401.	0.9	3
217	MicroRNA-based therapeutics for optic neuropathy: opportunities and challenges. <i>Neural Regeneration Research</i> , 2021, 16, 1996.	1.6	3
218	Nucleic Acids for Gene Therapy. , 2021, , 1-8.		0
219	Evolutionarily Conserved Long Non-coding RNA Regulates Gene Expression in Cytokine Storm During COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 582953.	2.0	33
220	siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID-19 Therapies?. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001650.	3.9	47
221	Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. <i>RNA Biology</i> , 2021, 18, 1048-1062.	1.5	24
222	Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. <i>Theranostics</i> , 2021, 11, 5248-5266.	4.6	122
223	Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects. <i>Pharmaceutics</i> , 2021, 13, 177.	2.0	18
224	Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 138.	1.8	23

#	ARTICLE	IF	CITATIONS
225	7â€²,5â€²-alpha-bicyclo-DNA: new chemistry for oligonucleotide exon splicing modulation therapy. <i>Nucleic Acids Research</i> , 2021, 49, 12089-12105.	6.5	6
226	Nucleosomes enter cells by clathrin- and caveolin-dependent endocytosis. <i>Nucleic Acids Research</i> , 2021, 49, 12306-12319.	6.5	4
227	Targeting 3â€² and 5â€² untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. <i>Nucleic Acids Research</i> , 2021, 49, 11560-11574.	6.5	10
228	Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression. <i>Cellular and Molecular Neurobiology</i> , 2021, , 1.	1.7	2
229	Antisense Oligonucleotide-Mediated Silencing of Mitochondrial Fusion and Fission Factors Modulates Mitochondrial Dynamics and Rescues Mitochondrial Dysfunction. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 51-65.	2.0	2
230	IUPAC Top Ten Emerging Technologies in Chemistry 2021. <i>Chemistry International</i> , 2021, 43, 13-20.	0.3	22
232	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. <i>Nature Communications</i> , 2021, 12, 6120.	5.8	13
233	The Scavenger Function of Liver Sinusoidal Endothelial Cells in Health and Disease. <i>Frontiers in Physiology</i> , 2021, 12, 757469.	1.3	50
234	Investigating the Activation Kinetics of Phosphoramidites for Oligonucleotide Synthesis. <i>Organic Process Research and Development</i> , 2022, 26, 764-772.	1.3	3
236	A gy ³ gyszerkutatás irányzatai: hatékony és biztonságos biztonsgosság. <i>Scientia Et Securitas</i> , 2021, 2, 177-183.		0
237	DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. <i>Oncogene</i> , 2022, 41, 83-98.	2.6	12
238	MCM3AP-AS1: An Indispensable Cancer-Related LncRNA. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 752718.	1.8	9
239	Future Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases. <i>Pharmaceutics</i> , 2021, 13, 1722.	2.0	4
240	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112282.	2.5	10
241	Multifunctional polymeric micelle-based nucleic acid delivery: Current advances and future perspectives. <i>Applied Materials Today</i> , 2021, 25, 101217.	2.3	21
243	Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy. <i>BioDrugs</i> , 2021, 35, 643-671.	2.2	8
244	Synthetic molecule libraries for nucleic acid delivery: Design parameters in cationic/ionizable lipids and polymers. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100428.	1.1	8
245	Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy. <i>Cells</i> , 2021, 10, 2957.	1.8	14

#	ARTICLE	IF	CITATIONS
246	ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11596.	1.8	20
247	Intron distribution and emerging role of alternative splicing in fungi. <i>FEMS Microbiology Letters</i> , 2021, 368, .	0.7	14
248	Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. <i>Cancers</i> , 2021, 13, 5361.	1.7	8
249	Cell Penetrating Peptides Used in Delivery of Therapeutic Oligonucleotides Targeting Hepatitis B Virus. <i>Pharmaceuticals</i> , 2020, 13, 483.	1.7	5
250	Regulatory Non-coding RNAs in Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2020, , 463-492.	0.9	13
251	The expression, function, and utilization of Protamine1: a literature review. <i>Translational Cancer Research</i> , 2021, 10, 4947-4957.	0.4	7
252	Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs. <i>Nucleic Acids Research</i> , 2021, 49, 12502-12516.	6.5	27
253	Systematic Combination of Oligonucleotides and Synthetic Polymers for Advanced Therapeutic Applications. <i>Macromolecular Research</i> , 2021, 29, 665-680.	1.0	7
254	Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation. <i>Cancers</i> , 2021, 13, 5555.	1.7	13
255	The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives. <i>Molecular Neurodegeneration</i> , 2021, 16, 76.	4.4	52
256	Improved In Vivo Delivery of Small RNA Based on the Calcium Phosphate Method. <i>Journal of Personalized Medicine</i> , 2021, 11, 1160.	1.1	6
258	Improved analyses of regulatory genome, transcriptome and gene function, mutation penetrance, and clinical applications. , 2022, , 95-132.		0
259	Expansion of methods of gene editing therapy and analysis of safety and efficacy. , 2022, , 155-179.		0
260	Evaluating Efficacy of Peptide-Delivered Oligonucleotides Using the Severe Taiwanese SMA Mouse Model. <i>Methods in Molecular Biology</i> , 2022, 2383, 491-513.	0.4	2
261	Suppression of Kv3.3 channels by antisense oligonucleotides reverses biochemical effects and motor impairment in spinocerebellar ataxia type 13 mice. <i>FASEB Journal</i> , 2021, 35, e22053.	0.2	5
263	Drug Design: Where We Are and Future Prospects. <i>Molecules</i> , 2021, 26, 7061.	1.7	5
264	Antisense Oligonucleotide-Based Therapy of Viral Infections. <i>Pharmaceutics</i> , 2021, 13, 2015.	2.0	26
265	The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint. <i>Cells</i> , 2021, 10, 3097.	1.8	31

#	ARTICLE	IF	CITATIONS
266	Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114041.	6.6	26
267	Pharmacological Activation of cGAS for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 753472.	2.2	13
268	Enhancing the Therapeutic Potential of Extracellular Vesicles Using Peptide Technology. <i>Methods in Molecular Biology</i> , 2022, 2383, 119-141.	0.4	5
269	Characterizing the Diastereoisomeric Distribution of Phosphorothioate Oligonucleotides by Metal Ion Complexation Chromatography, In-Series Reversed Phase-Strong Anion Exchange Chromatography, and ³¹ P NMR. <i>Analytical Chemistry</i> , 2021, 93, 16035-16042.	3.2	5
270	Further Studies on Cationic Gemini Amphiphiles as Carriers for Gene Delivery—The Effect of Linkers in the Structure and Other Factors Affecting the Transfection Efficacy of These Amphiphiles. <i>ACS Omega</i> , 2021, 6, 33370-33388.	1.6	1
271	Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm. <i>EBioMedicine</i> , 2021, 74, 103691.	2.7	33
272	Origin of Proteolytic Stability of Peptide-Brush Polymers as Globular Proteomimetics. <i>ACS Central Science</i> , 2021, 7, 2063-2072.	5.3	10
273	Novel Fluorinated Spermine and Small Molecule PEI to Deliver Anti-PD-L1 and Anti-VEGF siRNA for Highly Efficient Tumor Therapy. <i>Pharmaceutics</i> , 2021, 13, 2058.	2.0	4
274	A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems. <i>Frontiers in Nutrition</i> , 2021, 8, 783831.	1.6	57
275	PEG-Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response. <i>Advanced Materials</i> , 2022, 34, e2107852.	11.1	19
276	Combinational application of metal-organic frameworks-based nanozyme and nucleic acid delivery in cancer therapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1773.	3.3	16
278	Cancer immunomodulation using bispecific aptamers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 894-915.	2.3	20
279	Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 169, 106094.	1.9	24
280	Classification of breast cancer by a gold nanoparticle based multicolor fluorescent aptasensor. <i>Journal of Colloid and Interface Science</i> , 2022, 611, 287-293.	5.0	8
281	Oligonucleotide Therapeutics: From Discovery and Development to Patentability. <i>Pharmaceutics</i> , 2022, 14, 260.	2.0	50
282	Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy. <i>Biomaterials</i> , 2022, 280, 121324.	5.7	17
283	Lipid-Based Nanocarriers in Renal RNA Therapy. <i>Biomedicines</i> , 2022, 10, 283.	1.4	9
284	Construction of nanocarriers based on nucleic acids and their applications in nanobiology delivery systems. <i>National Science Review</i> , 2022, 9, .	4.6	22

#	ARTICLE	IF	CITATIONS
285	Insights into nucleic acid-based self-assembling nanocarriers for targeted drug delivery and controlled drug release. <i>Journal of Controlled Release</i> , 2022, 341, 869-891.	4.8	20
286	Assembly of Bleomycin Saccharide-Decorated Spherical Nucleic Acids. <i>Bioconjugate Chemistry</i> , 2022, 33, 206-218.	1.8	5
287	Enhanced anti-tumor activity of a drug through pH-triggered release and dual targeting by calcium phosphate-covered mesoporous silica vehicles. <i>Journal of Materials Chemistry B</i> , 2022, 10, 384-395.	2.9	13
288	Innovative approaches for treatment of osteosarcoma. <i>Experimental Biology and Medicine</i> , 2022, 247, 310-316.	1.1	18
289	Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1777.	3.3	6
290	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). <i>Nature Medicine</i> , 2022, 28, 96-103.	15.2	128
291	Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder. <i>Npj Genomic Medicine</i> , 2022, 7, 9.	1.7	8
292	Cell-penetrating poly(disulfide)-based nanoquenchers (CPDs) for self-monitoring of intracellular gene delivery. <i>Chemical Communications</i> , 2022, 58, 1792-1795.	2.2	6
293	Exosome as a Delivery Vehicle for Cancer Therapy. <i>Cells</i> , 2022, 11, 316.	1.8	34
294	Drug delivery systems for RNA therapeutics. <i>Nature Reviews Genetics</i> , 2022, 23, 265-280.	7.7	417
295	Meeting report: the 2021 FSHD International Research Congress. <i>Skeletal Muscle</i> , 2022, 12, 1.	1.9	12
296	Small-molecule degraders of cyclin-dependent kinase protein: a review. <i>Future Medicinal Chemistry</i> , 2022, 14, 167-185.	1.1	5
297	Systemic delivery of siRNA to the colon using peptide modified PEG-PCL polymer micelles for the treatment of ulcerative colitis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 170, 170-178.	2.0	12
298	Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development. <i>Molecules</i> , 2022, 27, 536.	1.7	39
299	Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. <i>Neurological Research and Practice</i> , 2022, 4, 2.	1.0	27
300	AMPK-autophagy-mediated inhibition of microRNA-30a-5p alleviates morphine tolerance via SOCS3-dependent neuroinflammation suppression. <i>Journal of Neuroinflammation</i> , 2022, 19, 25.	3.1	12
301	An Investigation into the Resistance of Spherical Nucleic Acids against DNA Enzymatic Degradation. <i>Bioconjugate Chemistry</i> , 2022, 33, 219-225.	1.8	7
302	Altered Biodistribution and Hepatic Safety Profile of a Capmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 177-184.	2.0	6

#	ARTICLE	IF	CITATIONS
303	How Do Biomolecules Cross the Cell Membrane?. <i>Accounts of Chemical Research</i> , 2022, 55, 309-318.	7.6	35
304	Nanocarriers for Delivery of Oligonucleotides to the CNS. <i>International Journal of Molecular Sciences</i> , 2022, 23, 760.	1.8	4
305	Targeted Delivery of Exosomes Armed with Anti-Cancer Therapeutics. <i>Membranes</i> , 2022, 12, 85.	1.4	17
308	Antisense Oligonucleotide-Related Macrovesicular Vacuolation of Hippocampal Neurons in Nonhuman Primates. <i>Toxicologic Pathology</i> , 2022, 50, 197-210.	0.9	6
309	Next-Generation Nonviral Vectors for mRNA Vaccine Delivery. <i>Macromolecular Chemistry and Physics</i> , 2022, 223, .	1.1	5
310	Gene Regulation Using Nanodiscs Modified with HIF-1- β Antisense Oligonucleotides. <i>Bioconjugate Chemistry</i> , 2022, 33, 279-293.	1.8	4
311	Chemically Synthesized, Self-Assembling Small Interfering RNA-Prohead RNA Molecules Trigger Dicer-Independent Gene Silencing. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	4
312	Challenges and Opportunities for Nucleic Acid Therapeutics. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 8-13.	2.0	29
313	Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing. <i>Nanoscale Advances</i> , 2022, 4, 2107-2123.	2.2	21
314	The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 851004.	2.2	12
315	Emerging new therapeutic antibody derivatives for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 39.	7.1	158
316	Oligodeoxynucleotides Modified with 2'-O-(Cysteinylaminobutyl)carbamoyl ethylribothymidine Residues for Native Chemical Ligation with Peptide at Internal Positions. <i>Bioconjugate Chemistry</i> , 2022, 33, 272-278.	1.8	2
317	Combinatorial Polycation Synthesis and Causal Machine Learning Reveal Divergent Polymer Design Rules for Effective pDNA and Ribonucleoprotein Delivery. <i>Jacs Au</i> , 2022, 2, 428-442.	3.6	22
318	Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	56
319	β Peptide Nucleic Acid-Based miR-122 Inhibition Rescues Vascular Endothelial Dysfunction in Mice Fed a High-Fat Diet. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3332-3342.	2.9	8
320	Antisense oligonucleotides: recent progress in the treatment of various diseases. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, .	0.8	2
321	The potential of long noncoding RNA therapies. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 269-280.	4.0	28
322	Current state of the art in peptide-based gene delivery. <i>Journal of Controlled Release</i> , 2022, 343, 600-619.	4.8	45

#	ARTICLE	IF	CITATIONS
323	Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. <i>Nature Biotechnology</i> , 2022, 40, 946-955.	9.4	63
324	The role of alternative splicing in human cancer progression. <i>American Journal of Cancer Research</i> , 2021, 11, 4642-4667.	1.4	3
325	Brain delivering RNA-based therapeutic strategies by targeting mTOR pathway for axon regeneration after central nervous system injury. <i>Neural Regeneration Research</i> , 2022, 17, 2157.	1.6	15
326	Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease. <i>Frontiers in Physiology</i> , 2022, 13, 839471.	1.3	4
327	Energy-resolved mass spectrometry to investigate nucleobase triplexes – a study applied to triplex-forming artificial nucleobases. <i>New Journal of Chemistry</i> , 0, , .	1.4	0
328	A dynamic DNA nanosponge for triggered amplification of gene-photodynamic modulation. <i>Chemical Science</i> , 2022, 13, 5155-5163.	3.7	12
330	Methodological advances of bioanalysis and biochemical targeting of intracellular G-quadruplexes. <i>Exploration</i> , 2022, 2, .	5.4	5
331	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 417-439.	21.5	24
332	Innovative developments and emerging technologies in RNA therapeutics. <i>RNA Biology</i> , 2022, 19, 313-332.	1.5	19
333	RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. <i>Molecular Cancer</i> , 2022, 21, 58.	7.9	33
334	Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc. <i>Molecular Pharmaceutics</i> , 2022, 19, 1104-1116.	2.3	6
336	Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. <i>Drug Metabolism and Disposition</i> , 2022, 50, 879-887.	1.7	32
338	Direct Anodic $\text{C}=\text{N}^+$ Hydroxylation: Accessing Versatile Intermediates for Azanucleoside Derivatives. <i>Asian Journal of Organic Chemistry</i> , 2022, 11, .	1.3	3
339	Inhomogeneous Diastereomeric Composition of Mogensen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 312-320.	2.0	8
340	Reprogramming RNA processing: an emerging therapeutic landscape. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 437-454.	4.0	14
341	Common and Rare 5'UTR Variants Altering Upstream Open Reading Frames in Cardiovascular Genomics. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 841032.	1.1	9
342	Exploring the Structural Diversity of DNA Bottlebrush Polymers Using an Oligonucleotide Macromonomer Approach. <i>Macromolecules</i> , 2022, 55, 2235-2242.	2.2	0
344	Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2751-2777.	5.7	27

#	ARTICLE	IF	CITATIONS
345	Fluorinated Nucleosides: Synthesis, Modulation in Conformation and Therapeutic Application. <i>Chemical Record</i> , 2022, 22, e202100335.	2.9	17
346	Structural Fingerprinting of siRNA Therapeutics by Solution NMR Spectroscopy. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 267-279.	2.0	2
347	Blood Transcriptome Analysis of Septic Patients Reveals a Long Non-Coding Alu-RNA in the Complement C5a Receptor 1 Gene. <i>Non-coding RNA</i> , 2022, 8, 24.	1.3	0
348	Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics. <i>BioDrugs</i> , 2022, 36, 181-196.	2.2	8
349	Programmable manipulation of oligonucleotide–albumin interaction for elongated circulation time. <i>Nucleic Acids Research</i> , 2022, 50, 3083-3095.	6.5	14
350	Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. <i>Cancers</i> , 2022, 14, 1588.	1.7	27
351	Oligonucleotic Probes and Immunosensors Based on Nanoporous Anodic Alumina for Screening of Diseases. <i>Advanced Materials Technologies</i> , 2022, 7, .	3.0	4
352	Emerging concepts of miRNA therapeutics: from cells to clinic. <i>Trends in Genetics</i> , 2022, 38, 613-626.	2.9	212
353	Dysregulation of Hepatitis B Virus Nucleocapsid Assembly in vitro by RNA-binding Small Ligands. <i>Journal of Molecular Biology</i> , 2022, 434, 167557.	2.0	6
354	Biocatalytic assembly of chemically modified oligonucleotides. <i>Tetrahedron Letters</i> , 2022, 93, 153696.	0.7	1
355	Epigenetic repression of gonadotropin gene expression via a GnRH-mediated DNA delivery system. <i>Gene Therapy</i> , 2022, , .	2.3	0
356	New therapeutics for primary hyperoxaluria type 1. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, Publish Ahead of Print, .	1.0	7
357	Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome. <i>Trends in Genetics</i> , 2022, 38, 920-943.	2.9	13
358	Current Advances in RNA Therapeutics for Human Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2736.	1.8	78
359	Advanced molecular imaging for the characterisation of complex medicines. <i>Drug Discovery Today</i> , 2022, 27, 1716-1723.	3.2	3
360	An Antisense Oligonucleotide for Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2022, 386, 1083-1085.	13.9	3
361	Continuous countercurrent chromatographic twin-column purification of oligonucleotides: The role of the displacement effect. <i>Biotechnology and Bioengineering</i> , 2022, 119, 1861-1872.	1.7	5
362	Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 919-932.	1.6	14

#	ARTICLE	IF	CITATIONS
363	Double-Headed 2'-Deoxynucleotides That Hybridize to DNA and RNA Targets via Normal and Reverse Watson-Crick Base Pairs. <i>Journal of Organic Chemistry</i> , 2022, 87, 5113-5124.	1.7	0
364	Systemic hypertonic saline enhances glymphatic spinal cord delivery of lumbar intrathecal morphine. <i>Journal of Controlled Release</i> , 2022, 344, 214-224.	4.8	9
365	Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate. <i>Pharmaceutics</i> , 2022, 14, 785.	2.0	0
366	New advances in exosome-based targeted drug delivery systems. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103628.	2.0	47
367	RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases. <i>Current Atherosclerosis Reports</i> , 2022, 24, 307-321.	2.0	12
369	Viral hepatitis: Past, present, and future. <i>World Journal of Gastroenterology</i> , 2022, 28, 1405-1429.	1.4	29
370	Designing electrospun fiber platforms for efficient delivery of genetic material and genome editing tools. <i>Advanced Drug Delivery Reviews</i> , 2022, 183, 114161.	6.6	21
371	RNA – A choice of potential drug delivery system. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2023, 72, 778-792.	1.8	2
372	PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs. <i>Journal of Controlled Release</i> , 2022, 345, 62-74.	4.8	6
373	Building machine-learning-based models for retention time and resolution predictions in ion pair chromatography of oligonucleotides. <i>Journal of Chromatography A</i> , 2022, 1671, 462999.	1.8	13
374	Can pulmonary RNA delivery improve our pandemic preparedness?. <i>Journal of Controlled Release</i> , 2022, 345, 549-556.	4.8	5
375	Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 345, 586-600.	4.8	12
376	Stability and context of intercalated motifs (i-motifs) for biological applications. <i>Biochimie</i> , 2022, 198, 33-47.	1.3	13
377	Anti-MicroRNA-21 Oligonucleotide Loaded Spermine-Modified Acetalated Dextran Nanoparticles for B1 Receptor-Targeted Gene Therapy and Antiangiogenesis Therapy. <i>Advanced Science</i> , 2022, 9, e2103812.	5.6	18
378	Enhanced Immunostimulatory Activity of Covalent DNA Dendrons. <i>ChemBioChem</i> , 2022, 23, .	1.3	9
379	CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials. <i>Pharmaceutics</i> , 2022, 14, 73.	2.0	25
380	Synthesis and Exon-Skipping Properties of a 3'-Ursodeoxycholic Acid-Conjugated Oligonucleotide Targeting DMD Pre-mRNA: Pre-Synthetic versus Post-Synthetic Approach. <i>Molecules</i> , 2021, 26, 7662.	1.7	2
381	Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery. <i>Pharmaceutics</i> , 2022, 14, 78.	2.0	49

#	ARTICLE	IF	CITATIONS
384	Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences. <i>Frontiers in Chemistry</i> , 2021, 9, 802766.	1.8	20
385	Challenges for the Development of Extracellular Vesicle-Based Nucleic Acid Medicines. <i>Cancers</i> , 2021, 13, 6137.	1.7	11
386	Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides. <i>Nucleic Acids Research</i> , 2022, 50, 17-34.	6.5	21
387	Self-Assembled Oligo-Urethane Nanoparticles: Their Characterization and Use for the Delivery of Active Biomolecules into Mammalian Cells. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 58352-58368.	4.0	3
388	Synthesis, gene silencing activity, thermal stability, and serum stability of siRNA containing four (<i>5'</i> - <i>3'</i> -aminopropyl-2'- <i>O</i> -methylnucleosides (A, adenosine; U, uridine; G, guanosine); Tj17Qq000rgBT/Ove	1.7	0
389	Targeting chromatin: Transcriptional gene activation (saRNA). , 2022, , 3-16.		0
390	Circular RNAs With Efficacy in Preclinical <i>In Vitro</i> and <i>In Vivo</i> Models of Esophageal Squamous Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 283-298.	1.0	3
391	Pure DNA scaffolded drug delivery systems for cancer therapy. <i>Biomaterials</i> , 2022, 285, 121532.	5.7	9
392	Advancements in the characterisation of oligonucleotides by high performance liquid chromatography-mass spectrometry in 2021: A short review. <i>Analytical Science Advances</i> , 2022, 3, 90-102.	1.2	8
393	Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 350-359.	2.0	2
394	Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and <i>In Vitro</i> Evaluation of Exon Skipping in Duchenne Muscular Dystrophy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4270.	1.8	4
395	Targeting non-coding RNAs to overcome cancer therapy resistance. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 121.	7.1	114
396	Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example. <i>Life</i> , 2022, 12, 608.	1.1	1
397	Function and Therapeutic Implications of tRNA Derived Small RNAs. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 888424.	1.6	10
398	Nanodelivery of nucleic acids. <i>Nature Reviews Methods Primers</i> , 2022, 2, .	11.8	146
399	RNA therapy: rich history, various applications and unlimited future prospects. <i>Experimental and Molecular Medicine</i> , 2022, 54, 455-465.	3.2	92
400	Signaling cascades in the failing heart and emerging therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 134.	7.1	18
401	A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 833833.	2.0	9

#	ARTICLE	IF	CITATIONS
403	A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer. <i>Chemical Science</i> , 2022, 13, 5345-5352.	3.7	16
404	Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. <i>RNA Biology</i> , 2022, 19, 594-608.	1.5	23
405	RNAi-based modulation of IFN- β signaling in skin. <i>Molecular Therapy</i> , 2022, 30, 2709-2721.	3.7	13
406	A Lysosome-Activated Tetrahedral Nanobox for Encapsulated siRNA Delivery. <i>Advanced Materials</i> , 2022, 34, e2201731.	11.1	79
407	Pytheas: a software package for the automated analysis of RNA sequences and modifications via tandem mass spectrometry. <i>Nature Communications</i> , 2022, 13, 2424.	5.8	13
408	The interactions between DNA nanostructures and cells: A critical overview from a cell biology perspective. <i>Acta Biomaterialia</i> , 2022, 146, 10-22.	4.1	10
409	Amphiphilic Dendrimer Vectors for RNA Delivery: State-of-the-Art and Future Perspective. <i>Accounts of Materials Research</i> , 2022, 3, 484-497.	5.9	19
410	Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidiny/Cationic Lipid against Hepatocellular Carcinoma. <i>Molecular Pharmaceutics</i> , 2022, 19, 4552-4564.	2.3	6
411	Spatial analysis of drug absorption, distribution, metabolism, and toxicology using mass spectrometry imaging. <i>Biochemical Pharmacology</i> , 2022, 201, 115080.	2.0	17
412	Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond. <i>Inflammation Research</i> , 2022, 71, 729-739.	1.6	3
413	Enhancement of Regnase-1 expression with stem loop-targeting antisense oligonucleotides alleviates inflammatory diseases. <i>Science Translational Medicine</i> , 2022, 14, eabo2137.	5.8	8
414	The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114316.	6.6	17
415	The Progress and Promise of RNA Medicine—An Arsenal of Targeted Treatments. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6975-7015.	2.9	42
416	The potential of RNA-based therapy for kidney diseases. <i>Pediatric Nephrology</i> , 2023, 38, 327-344.	0.9	14
417	Casimersen for the treatment of Duchenne muscular dystrophy. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 607-608.	4.0	12
418	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A) Recommendations on Endogenous Compounds, Small Molecules.) Tj ETQq, 1 0.784314 rgBT	1.1	14
419	Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	4
420	High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization. <i>Bioanalysis</i> , 2022, 14, 603-613.	0.6	3

#	ARTICLE	IF	CITATIONS
421	Simultaneous quantification of oligo-nucleic acids and a ferritin nanocage by size-exclusion chromatography hyphenated to inductively coupled plasma mass spectrometry for developing drug delivery systems. <i>Analytical Methods</i> , 2022, 14, 2219-2226.	1.3	2
422	Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment. <i>Theranostics</i> , 2022, 12, 3911-3927.	4.6	3
423	CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4 Fatty Acid Oxidation Pathway. <i>Advanced Science</i> , 2022, 9, .	5.6	26
425	Dermal nanomedicine: Uncovering the ability of nucleic acid to alleviate autoimmune and other related skin disorders. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 73, 103437.	1.4	1
426	Advances in the design of new types of inhaled medicines. <i>Progress in Medicinal Chemistry</i> , 2022, , 93-162.	4.1	3
427	Enrichment and Recovery of Oligonucleotide Impurities by N-Rich Twin-Column Continuous Chromatography. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
428	Development of Therapeutic RNA Manipulation for Muscular Dystrophy. <i>Frontiers in Genome Editing</i> , 0, 4, .	2.7	5
429	Antisense modulation of IL7R splicing to control sIL7R expression in human CD4 ⁺ T cells. <i>Rna</i> , 2022, 28, 1058-1073.	1.6	1
430	The Usefulness of Autoradiography for DNA Repair Proteins Activity Detection in the Cytoplasm towards Radiolabeled Oligonucleotides Containing 5 ² ,8-Cyclo-2 ² -deoxyadenosine. <i>Chemosensors</i> , 2022, 10, 204.	1.8	0
431	Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy. <i>Cells</i> , 2022, 11, 1805.	1.8	3
432	FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?. <i>Journal of Personalized Medicine</i> , 2022, 12, 865.	1.1	3
433	Strategies for the Synthesis of Fluorinated Nucleosides, Nucleotides and Oligonucleotides. <i>Chemical Record</i> , 2022, 22, .	2.9	8
434	Antisense Oligonucleotides for the Study and Treatment of ALS. <i>Neurotherapeutics</i> , 2022, 19, 1145-1158.	2.1	26
435	MicroRNAs as therapeutic targets in cardiovascular disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	50
436	Genetic therapeutic advancements for Dravet Syndrome. <i>Epilepsy and Behavior</i> , 2022, 132, 108741.	0.9	10
438	Nucleic Acids for Gene Therapy. , 2022, , 707-715.		0
439	Small Activating RNA Modulation of the G Protein-Coupled Receptor for Cancer Treatment. <i>Advanced Science</i> , 2022, 9, .	5.6	10
440	Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 189-203.	2.3	4

#	ARTICLE	IF	CITATIONS
441	Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders. <i>Frontiers in Genome Editing</i> , 0, 4, .	2.7	6
442	Inhaled siRNA nanoparticles targeting <i>IL11</i> inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. <i>Science Advances</i> , 2022, 8, .	4.7	46
443	Long Non-Coding RNA MCM3AP-AS1: A Crucial Role in Human Malignancies. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	2
444	Exosomally Targeting microRNA23a Ameliorates Microvascular Endothelial Barrier Dysfunction Following Rickettsial Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
445	Recent Advances in DNA Nanotechnology for Plasmonic Biosensor Construction. <i>Biosensors</i> , 2022, 12, 418.	2.3	5
446	Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsiesâ€”a Study in a Tertiary Epilepsy Center. <i>Neurotherapeutics</i> , 2022, 19, 1353-1367.	2.1	14
447	Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside. <i>International Journal of Nephrology and Renovascular Disease</i> , 0, Volume 15, 197-206.	0.8	7
448	Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease. <i>Toxicological Sciences</i> , 2022, 189, 237-249.	1.4	5
449	DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 162-175.	2.3	3
450	Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
451	RNA therapies for cardiovascular disease. , 2022, , 413-425.		0
452	Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics. <i>RSC Advances</i> , 2022, 12, 20432-20446.	1.7	5
453	RNA editing of ion channels and receptors in physiology and neurological disorders. , 2022, 1, .		2
454	Molecular ZIP codes in targeted drug delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
455	Targeting the â€œundruggableâ€ RNA-binding proteins in the spotlight in cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 69-83.	4.3	11
456	Electrospun-Fibrous-Architecture-Mediated Non-Viral Gene Therapy Drug Delivery in Regenerative Medicine. <i>Polymers</i> , 2022, 14, 2647.	2.0	7
457	Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2. <i>Journal of Autoimmunity</i> , 2022, 131, 102857.	3.0	6
458	Applications of Artificial Intelligence and Machine Learning Algorithms to Crystallization. <i>Chemical Reviews</i> , 2022, 122, 13006-13042.	23.0	28

#	ARTICLE	IF	CITATIONS
459	New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. <i>Current Cardiovascular Risk Reports</i> , 2022, 16, 69-78.	0.8	5
460	Drug Discovery Study Aimed at a Functional Cure for HBV. <i>Viruses</i> , 2022, 14, 1393.	1.5	5
461	Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease. <i>JACC Basic To Translational Science</i> , 2022, 7, 956-969.	1.9	10
462	ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7127.	1.8	1
463	<scp>RNA</scp> therapeutics in the clinic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	31
464	Intracellular Absolute Quantification of Oligonucleotide Therapeutics by NanoSIMS. <i>Analytical Chemistry</i> , 2022, 94, 10549-10556.	3.2	2
465	Emerging Roles of Long Noncoding RNAs in Breast Cancer Epigenetics and Epitranscriptomics. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
466	The Role of microRNA in the Development, Diagnosis, and Treatment of Cardiovascular Disease: Recent Developments. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 123-132.	1.3	20
467	Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9507-9530.	2.9	14
468	RNA-targeting strategies as a platform for ocular gene therapy. <i>Progress in Retinal and Eye Research</i> , 2023, 92, 101110.	7.3	10
469	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. <i>Journal of Clinical Medicine</i> , 2022, 11, 3884.	1.0	22
470	Recent progress and perspectives of continuous in vivo testing device. <i>Materials Today Bio</i> , 2022, 16, 100341.	2.6	4
471	Tuning the Stability of the Polyplex Nanovesicles of Oligonucleotides via a Zinc (II)-Coordinative Strategy. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2022, 40, 1034-1042.	2.0	1
472	Microfluidics-Assisted Fluorescence Mapping of DNA Phosphorothioation. <i>Analytical Chemistry</i> , 2022, 94, 10479-10486.	3.2	1
473	ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	9
474	Accelerating space radiation countermeasure development through drug repurposing. <i>Life Sciences in Space Research</i> , 2022, 35, 30-35.	1.2	3
475	Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs. <i>Pharmaceutics</i> , 2022, 14, 1453.	2.0	6
476	Analytical techniques for characterizing diastereomers of phosphorothioated oligonucleotides. <i>Journal of Chromatography A</i> , 2022, 1678, 463349.	1.8	9

#	ARTICLE	IF	CITATIONS
477	An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides. <i>Nature Communications</i> , 2022, 13, .	5.8	16
478	HARIBOSS: a curated database of RNA-small molecules structures to aid rational drug design. <i>Bioinformatics</i> , 2022, 38, 4185-4193.	1.8	11
479	Emerging therapies for Duchenne muscular dystrophy. <i>Lancet Neurology</i> , The, 2022, 21, 814-829.	4.9	35
480	RNA solutions to treat inborn errors of metabolism. <i>Molecular Genetics and Metabolism</i> , 2022, 136, 289-295.	0.5	6
481	Analysis of therapeutic nucleic acids by capillary electrophoresis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 219, 114928.	1.4	10
482	Targeting the RNA G-Quadruplex and Protein Interactome for Antiviral Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 10161-10182.	2.9	9
483	MOPSS: Toward high-fidelity oligonucleotides for clinical applications. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
484	Synthesis of a Convertible Linker Containing a Disulfide Group for Oligonucleotide Functionalization. <i>Organic Letters</i> , 0, , .	2.4	4
485	Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases. <i>Advanced Science</i> , 2022, 9, .	5.6	19
486	Constructing a nanocage-based universal carrier for delivering TLR-activating nucleic acids to enhance antitumor immunotherapy. <i>Nano Today</i> , 2022, 46, 101564.	6.2	13
487	Perfluoroalkyl-containing Compounds as a Tool for Drug Delivery Systems. , 2022, , 477-515.		2
488	UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs. <i>Neuroscience Bulletin</i> , 0, , .	1.5	0
489	MicroRNAs and Their Big Therapeutic Impacts: Delivery Strategies for Cancer Intervention. <i>Cells</i> , 2022, 11, 2332.	1.8	19
490	The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides. <i>Pharmaceuticals</i> , 2022, 15, 909.	1.7	15
491	Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. <i>Genes</i> , 2022, 13, 1426.	1.0	4
492	Efficient and Improved Solution-Phase Synthesis of Modified RNA Dinucleotides: Versatile Synthons in Cap 1 mRNA Therapeutics. <i>Organic Process Research and Development</i> , 2022, 26, 2771-2778.	1.3	4
493	An intranasal ASO therapeutic targeting SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	5.8	29
494	New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8529.	1.8	19

#	ARTICLE	IF	CITATIONS
495	Role of a "Magic" Methyl: 2-Deoxy-2-F-2-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5-Phosphate Mimics and Mitigation of Off-Target Effects. <i>Journal of the American Chemical Society</i> , 2022, 144, 14517-14534.	6.6	7
496	Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2022, 14, 1708.	2.0	17
497	Self-Assembled DNA-Protein Hybrid Nanospheres: Biocompatible Nano-Drug-Carriers for Targeted Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 37493-37503.	4.0	3
498	The role of LncRNA MCM3AP-AS1 in human cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	5
499	MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. <i>Molecular Metabolism</i> , 2022, 65, 101581.	3.0	31
500	PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression. <i>Nature Communications</i> , 2022, 13, .	5.8	17
501	Gene therapy to enhance angiogenesis in chronic wounds. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 871-899.	2.3	18
502	PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 547-561.	1.8	5
503	Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development. <i>Biomedicines</i> , 2022, 10, 1865.	1.4	14
504	Application of lipid-based nanoparticles in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
505	Role of computational and structural biology in the development of small-molecule modulators of the spliceosome. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 1095-1109.	2.5	6
506	Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. <i>Clinical Therapeutics</i> , 2022, 44, 1237-1247.	1.1	13
507	Approved gene therapies in Australia: coming to a store near you. <i>Internal Medicine Journal</i> , 2022, 52, 1313-1321.	0.5	3
508	The glymphatic system: implications for drugs for central nervous system diseases. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 763-779.	21.5	47
510	Noncoding RNAs and RNA-binding proteins: emerging governors of liver physiology and metabolic diseases. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C1003-C1017.	2.1	8
511	DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer. <i>Molecular Therapy</i> , 2023, 31, 471-486.	3.7	12
512	Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 955-968.	2.3	4
513	Benzoyl and Pivaloyl as Efficient Protecting Groups for Controlled Enzymatic Synthesis of DNA and XNA Oligonucleotides. <i>Asian Journal of Organic Chemistry</i> , 2022, 11, .	1.3	8

#	ARTICLE	IF	CITATIONS
514	CaMKII as a Therapeutic Target in Cardiovascular Disease. Annual Review of Pharmacology and Toxicology, 2023, 63, 249-272.	4.2	22
515	Synthesis and physical and biological properties of 1,3-diaza-2-oxophenoxazine-conjugated oligonucleotides. Bioorganic and Medicinal Chemistry, 2022, 72, 116972.	1.4	3
516	Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies. Molecular Therapy - Nucleic Acids, 2022, 29, 625-642.	2.3	10
517	Influence of protein corona on the interaction of glycogenâ€siRNA constructs with ex vivo human blood immune cells. , 2022, 140, 213083.		0
518	Oligonucleotide-based therapies for cystic fibrosis. Current Opinion in Pharmacology, 2022, 66, 102271.	1.7	2
519	Rapid identification of short oligonucleotide impurities using lithium adduct consolidated MALDI-TOF mass spectrometry. International Journal of Mass Spectrometry, 2022, 481, 116913.	0.7	0
520	Nucleic acid-based therapeutics for dermal wound healing. International Journal of Biological Macromolecules, 2022, 220, 920-933.	3.6	14
521	Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy. Journal of Hepatology, 2022, 77, 906-908.	1.8	2
522	Enrichment and recovery of oligonucleotide impurities by N-Rich twin-column continuous chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1209, 123439.	1.2	3
523	Multifunctional magnetic nanocarriers for delivery of siRNA and shRNA plasmid to mammalian cells: Characterization, adsorption and release behaviors. Colloids and Surfaces B: Biointerfaces, 2022, 219, 112861.	2.5	4
524	Structural investigation of Fe(III)-salen complexes as âœurn-onâœurn-fluorogenic probes for selective detection of pyrophosphate ions. Dyes and Pigments, 2022, 207, 110708.	2.0	6
525	A potential therapeutic approach for tauopathies. Molecular Therapy - Nucleic Acids, 2022, 30, 15-16.	2.3	1
526	Interplay of LncRNAs NEAT1 and TUG1 in Incidence of Cytokine Storm in Appraisal of COVID-19 Infection. International Journal of Biological Sciences, 2022, 18, 4901-4913.	2.6	9
527	Promotion of cytoplasmic localization of oligonucleotides by connecting cross-linked duplexes. RSC Advances, 2022, 12, 24471-24477.	1.7	0
528	Clinical applications of microRNAs. , 2022, , 601-612.		0
529	The Chemical Synthesis of DNA and RNA Oligonucleotides for Drug Development and Therapeutic Applications. , 2022, , .		0
530	Peptides and Oligonucleotide-Based Therapy: Bioanalytical Challenges and Practical Solutions. AAPS Advances in the Pharmaceutical Sciences Series, 2022, , 131-155.	0.2	1
531	Ferrocene as a potential electrochemical reporting surrogate of abasic sites in DNA. Organic and Biomolecular Chemistry, 2022, 20, 8125-8135.	1.5	4

#	ARTICLE	IF	CITATIONS
532	Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 4047-4061.	1.2	2
533	Preparation, applications, and challenges of functional DNA nanomaterials. <i>Nano Research</i> , 2023, 16, 3895-3912.	5.8	11
534	Microwave-assisted synthesis of functionalized carbazoles via palladium-catalyzed aryl C-H activation and study of their interactions with calf-thymus DNA. <i>Synthetic Communications</i> , 2022, 52, 1834-1855.	1.1	2
535	CureHeart wins Big Beat Challenge, a £30 million research award from the British Heart Foundation. <i>European Heart Journal</i> , 0, , .	1.0	0
536	Artificial Nucleobase-Directed Programmable Synthesis and Assembly of Amphiphilic Nucleic Acids as an All-in-One Platform for Cation-Free siRNA Delivery. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 44019-44028.	4.0	4
537	Site-Specific Radioiodination of Oligonucleotides with a Phenolic Element in a Programmable Approach. <i>Molecules</i> , 2022, 27, 6257.	1.7	0
538	Size-tunable lipid vectors for controlled local delivery of siRNA from gene activated matrix. <i>Acta Biomaterialia</i> , 2022, 153, 97-107.	4.1	4
539	DNA Strand Displacement with Base Pair Stabilizers: Purine 2,6-diamine and 8-azabromo-7-deazapurine 2,6-diamine Oligonucleotides Invade DNA and Fluorescent Pyrene Click Sensors Monitor the Reaction. <i>Chemistry - A European Journal</i> , 0, , .	3.5	3
541	Lipid-based nucleic acid therapeutics with in vivo efficacy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	3
542	The emergence of AntibodyPlus: the future trend of antibody-based therapeutics. <i>Antibody Therapeutics</i> , 2022, 5, 280-287.	1.2	3
543	Mechanism of endosomal escape by H -responsive nucleic-acid vectors. <i>Physical Review E</i> , 2022, 106, .	0.8	1
544	Natural and Modified Oligonucleotide Sequences Show Distinct Strand Displacement Kinetics and These Are Affected Further by Molecular Crowders. <i>Biomolecules</i> , 2022, 12, 1249.	1.8	0
545	Delivery of miRNAs through Metal-Organic Framework Nanoparticles for Assisting Neural Stem Cell Therapy for Ischemic Stroke. <i>ACS Nano</i> , 2022, 16, 14503-14516.	7.3	25
547	Natural antisense transcripts as drug targets. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
548	Current understanding on long non-coding RNAs in immune response to COVID-19. <i>Virus Research</i> , 2023, 323, 198956.	1.1	5
550	Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	12
552	Development of the Right- and Left-Handed Gamma Peptide Nucleic Acid Building Blocks for On-Resin Chemical Functionalization. <i>Journal of Organic Chemistry</i> , 2022, 87, 13873-13881.	1.7	1
553	Structural Fingerprinting of Antisense Oligonucleotide Therapeutics by Solution NMR Spectroscopy. <i>Pharmaceutical Research</i> , 0, , .	1.7	1

#	ARTICLE	IF	CITATIONS
554	Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy. <i>Journal of Controlled Release</i> , 2022, 351, 713-726.	4.8	12
555	Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 379-397.	2.3	3
556	Advancing New Chemical Modalities into Clinical Studies. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1691-1698.	1.3	13
557	The evolution and polymorphism of mono-amino acid repeats in androgen receptor and their regulatory role in health and disease. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
558	Analysis of key genes in <i>Mycobacterium ulcerans</i> reveals conserved RNA structural motifs and regions with apparent pressure to remain unstructured. <i>Frontiers in Tropical Diseases</i> , 0, 3, .	0.5	0
559	Dendrimerâ€siRNA Conjugates for Targeted Intracellular Delivery in Glioblastoma Animal Models. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 46290-46303.	4.0	13
560	Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges. <i>Pharmaceutics</i> , 2022, 14, 2236.	2.0	10
561	Small-Molecule 3D Ligand for RNA Recognition: Tuning Selectivity through Scaffold Hopping. <i>ACS Chemical Biology</i> , 2022, 17, 3069-3076.	1.6	1
562	Boron Clusters as Enhancers of RNase H Activity in the Smart Strategy of Gene Silencing by Antisense Oligonucleotides. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12190.	1.8	8
563	Fast Electron Detachment Dissociation of Oligonucleotides in Electron-Nitrogen Plasma Stored in Magneto Radio-Frequency Ion Traps. <i>Analytical Chemistry</i> , 2022, 94, 15510-15517.	3.2	4
564	Nanomedicine for Treating Muscle Dystrophies: Opportunities, Challenges, and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12039.	1.8	5
565	Modified Nucleotides for Chemical and Enzymatic Synthesis of Therapeutic RNA. <i>Current Medicinal Chemistry</i> , 2023, 30, 1320-1347.	1.2	3
566	Site-directed RNA editing by harnessing ADARs: advances and challenges. <i>Functional and Integrative Genomics</i> , 2022, 22, 1089-1103.	1.4	6
567	Hydroxyl-Rich Hydrophilic Endocytosis-Promoting Peptide with No Positive Charge. <i>Journal of the American Chemical Society</i> , 2022, 144, 20288-20297.	6.6	8
568	Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors. <i>Pharmaceutics</i> , 2022, 15, 1295.	1.7	2
569	Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities. <i>Xenobiotica</i> , 2022, 52, 840-854.	0.5	3
570	Navigating the Multiverse of Antisense RNAs: The Transcription- and RNA-Dependent Dimension. <i>Non-coding RNA</i> , 2022, 8, 74.	1.3	7
571	Nucleic Acid Aptamers for Pesticides, Toxins& Biomarkers in Agriculture. <i>ChemPlusChem</i> , 0, , .	1.3	1

#	ARTICLE	IF	CITATIONS
572	Generation of 4 ϵ^2 -Carbon Radicals via 1,5-Hydrogen Atom Transfer for the Synthesis of Bridged Nucleosides. <i>Organic Letters</i> , 2022, 24, 7696-7700.	2.4	2
575	Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA. <i>Clinical Cancer Research</i> , 2023, 29, 271-278.	3.2	11
576	Silencing mouse circular RNA circSlc8a1 by circular antisense cA-circSlc8a1 induces cardiac hepatopathy. <i>Molecular Therapy</i> , 2023, 31, 1688-1704.	3.7	4
577	Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report. <i>American Journal of Kidney Diseases</i> , 2022, , .	2.1	2
579	Cationic Micelles Outperform Linear Polymers for Delivery of Antisense Oligonucleotides in Serum: An Exploration of Polymer Architecture, Cationic Moieties, and Cell Addition Order. <i>Bioconjugate Chemistry</i> , 2022, 33, 2121-2131.	1.8	7
580	Oligonucleotides: A novel area of interest for drug delivery in neurodegenerative diseases. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 77, 103849.	1.4	2
581	Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13359.	1.8	8
582	Anti-angiogenic properties of microRNA-29a in preclinical ocular models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	4
583	Antiviral Activity of Oligonucleotides Targeting the SARS-CoV-2 Genomic RNA Stem-Loop Sequences within the 3 ϵ^2 -End of the ORF1b. <i>Pathogens</i> , 2022, 11, 1286.	1.2	2
584	Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
585	Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies. <i>International Journal of Pharmaceutics</i> , 2022, 628, 122299.	2.6	5
586	Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression. , 2022, 10, e005503.		3
587	A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. <i>EBioMedicine</i> , 2022, 85, 104304.	2.7	28
588	Separation of phosphorothioate oligonucleotide impurities by WAX HPLC under high organic content elution conditions. <i>Analytical Biochemistry</i> , 2022, 659, 114956.	1.1	4
589	Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies. <i>Journal of Controlled Release</i> , 2022, 352, 121-145.	4.8	10
590	Radiolabelling small and biomolecules for tracking and monitoring. <i>RSC Advances</i> , 2022, 12, 32383-32400.	1.7	11
591	RNA-based therapies in inherited retinal diseases. <i>Therapeutic Advances in Ophthalmology</i> , 2022, 14, 251584142211346.	0.8	6
592	Splicing and Editing to Fine-Tune Activity of High Voltage-Activated Calcium Channels. , 2022, , 47-72.		0

#	ARTICLE	IF	CITATIONS
593	A mechanistic study on the cellular uptake, intracellular trafficking, and antisense gene regulation of bottlebrush polymer-conjugated oligonucleotides. <i>RSC Chemical Biology</i> , 2023, 4, 138-145.	2.0	3
594	Strategies and challenges for non-viral delivery of non-coding RNAs to the heart. <i>Trends in Molecular Medicine</i> , 2023, 29, 70-91.	3.5	6
595	miRNA and antisense oligonucleotide-based Î±-synuclein targeting as disease-modifying therapeutics in Parkinson's disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
596	Liver-directed drugs for transthyretin-mediated amyloidosis. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 228-237.	1.4	4
597	DNA-Encoded Library Screening To Inform Design of a Ribonuclease Targeting Chimera (RiboTAC). <i>Journal of the American Chemical Society</i> , 2022, 144, 21096-21102.	6.6	20
598	CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting. <i>Pharmaceutical Research</i> , 2023, 40, 77-105.	1.7	9
599	2â€²â€³ oligoadenylate synthetase-like 1 (OASL1) protects against atherosclerosis by maintaining endothelial nitric oxide synthase mRNA stability. <i>Nature Communications</i> , 2022, 13, .	5.8	8
600	Full-Length Transcript Phasing with Third-Generation Sequencing. <i>Methods in Molecular Biology</i> , 2023, , 49-57.	0.4	1
601	Advances in mRNA nanomedicines for malignant brain tumor therapy. <i>Smart Materials in Medicine</i> , 2022, , .	3.7	3
602	On the Influence of Nucleic Acid Backbone Modifications on Lipid Nanoparticle Morphology. <i>Langmuir</i> , 2022, 38, 14036-14043.	1.6	5
603	Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
604	miR-328-3p Affects Axial Length Via Multiple Routes and Anti-miR-328-3p Possesses a Potential to Control Myopia Progression. , 2022, 63, 11.		1
605	Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. <i>Journal of Controlled Release</i> , 2022, 352, 861-878.	4.8	21
606	Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy. <i>Methods in Molecular Biology</i> , 2023, , 209-237.	0.4	2
607	Exon-Skipping for a Pathogenic COL6A1 Variant in Ullrich Congenital Muscular Dystrophy. <i>Methods in Molecular Biology</i> , 2023, , 387-407.	0.4	0
608	Binding assay of human Dectin-1 variants for DNA/Î²-glucan complex for active-targeting delivery of antisense DNA: Part II. <i>Carbohydrate Research</i> , 2023, 523, 108731.	1.1	2
609	Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. <i>Journal of Controlled Release</i> , 2023, 353, 241-253.	4.8	20
610	Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2023, 192, 114624.	6.6	10

#	ARTICLE	IF	CITATIONS
611	Albumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeutics. <i>Journal of Controlled Release</i> , 2023, 353, 166-185.	4.8	17
612	Development and multicenter validation of an LC-MS-based bioanalytical method for antisense therapeutics. <i>Bioanalysis</i> , 2022, 14, 1213-1227.	0.6	2
613	Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, .	3.3	12
614	Current Status of Natural Products/siRNA Co-Delivery for Cancer Therapy. <i>ChemistrySelect</i> , 2022, 7, .	0.7	0
615	Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders. <i>Journal of Personalized Medicine</i> , 2022, 12, 1979.	1.1	3
616	RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling <i>YRDC</i> Translation in NSCLC Cells. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, 21, 850-865.	3.0	4
617	Cancer Stem Cells—The Insight into Non-Coding RNAs. <i>Cells</i> , 2022, 11, 3699.	1.8	2
618	Is There a Role for Immunoregulatory and Antiviral Oligonucleotides Acting in the Extracellular Space? A Review and Hypothesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14593.	1.8	1
619	Innovative approaches in transforming <i>microRNAs</i> into therapeutic tools. <i>Wiley Interdisciplinary Reviews RNA</i> , 2023, 14, .	3.2	18
620	Evolution of complexity in non-viral oligonucleotide delivery systems: from gymnotic delivery through bioconjugates to biomimetic nanoparticles. <i>RNA Biology</i> , 2022, 19, 1256-1275.	1.5	10
621	Development of Phosphoramidite Reagents for the Synthesis of Base-Labile Oligonucleotides Modified with a Linear Aminoalkyl and Amino-PEG Linker at the 3'-End. <i>Molecules</i> , 2022, 27, 8501.	1.7	0
622	Non-coding RNAs in stroke pathology, diagnostics, and therapeutics. <i>Neurochemistry International</i> , 2023, 162, 105467.	1.9	1
623	A simple and green solid phase extraction method for oligonucleotides using adsorbent with amino and carboxylic moieties. <i>Talanta</i> , 2023, 255, 124224.	2.9	1
625	Lipid-Peptide-mRNA Nanoparticles Augment Radioiodine Uptake in Anaplastic Thyroid Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	6
626	Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles. <i>Advanced Healthcare Materials</i> , 0, , 2202412.	3.9	2
627	Targeted Protein Degradation: Clinical Advances in the Field of Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15440.	1.8	8
628	Nitrosamine Risk Assessments in Oligonucleotides. <i>Organic Process Research and Development</i> , 0, , .	1.3	0
629	Heteroatoms (B, N, S) doped quantum dots as potential drug delivery system for isoniazid: insight from DFT, NCI, and QTAIM. <i>Heliyon</i> , 2023, 9, e12599.	1.4	30

#	ARTICLE	IF	CITATIONS
630	Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	1
631	Potential of RH5 Antisense on Plasmodium falciparum Proliferation Abatement. <i>Iranian Journal of Parasitology</i> , 0, , .	0.6	0
632	Structural-Based Stability Enhancement of Antisense DNA Oligonucleotides. <i>Macromolecular Bioscience</i> , 2023, 23, .	2.1	1
633	Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 211-223.	2.3	6
634	Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 78, 117149.	1.4	1
635	Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 606-620.	2.3	2
636	Artificial genetic polymers against human pathologies. <i>Biology Direct</i> , 2022, 17, .	1.9	1
637	Liquid crystal phase formation and non-Newtonian behavior of oligonucleotide formulations. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 181, 270-281.	2.0	2
638	Refractive Index to Monitor Solid-Phase Oligonucleotide Synthesis. <i>Organic Process Research and Development</i> , 2023, 27, 65-77.	1.3	2
639	Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. <i>Journal of Endocrinology</i> , 2023, 256, .	1.2	1
640	Nano-Immunomodulation: A New Strategy for Skeletal Muscle Diseases and Aging?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1175.	1.8	0
641	Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 339-351.	2.3	3
642	Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis. <i>Journal of Cystic Fibrosis</i> , 2023, 22, S39-S44.	0.3	5
643	Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges. <i>Pharmaceutics</i> , 2023, 15, 237.	2.0	3
644	Improved Metal-Free Approach for the Synthesis of Protected Thiol Containing Thymidine Nucleoside Phosphoramidite and Its Application for the Synthesis of Ligatable Oligonucleotide Conjugates. <i>Pharmaceutics</i> , 2023, 15, 248.	2.0	0
645	Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development. <i>Accounts of Chemical Research</i> , 2023, 56, 224-236.	7.6	10
646	Multivalent Lactobionic Acid and N-Acetylgalactosamine-Conjugated Peptide Nucleic Acids for Efficient In Vivo Targeting of Hepatocytes. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	2
647	What Can RNA-Based Therapy Do for Monogenic Diseases?. <i>Pharmaceutics</i> , 2023, 15, 260.	2.0	1

#	ARTICLE	IF	CITATIONS
648	From green innovations in oligopeptide to oligonucleotide sustainable synthesis: differences and synergies in TIDES chemistry. <i>Green Chemistry</i> , 0, , .	4.6	7
649	Effective carrier-free gene-silencing activity of sphingosine-modified siRNAs. <i>Organic and Biomolecular Chemistry</i> , 0, , .	1.5	1
650	Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides. <i>Archives of Pharmacal Research</i> , 2023, 46, 18-34.	2.7	23
651	Comprehensive evaluation of zwitterionic hydrophilic liquid chromatography stationary phases for oligonucleotide characterization. <i>Journal of Chromatography A</i> , 2023, 1690, 463785.	1.8	5
652	Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2023, 183, 61-73.	2.0	3
653	Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery. <i>Journal of Drug Delivery Science and Technology</i> , 2023, 80, 104152.	1.4	1
654	Chemically modified small interfering RNA targeting Hedgehog signaling pathway for rheumatoid arthritis therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 88-104.	2.3	5
655	Machine Learning Informs RNAâ€Binding Chemical Space**. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	18
656	Machine Learning Informs RNAâ€Binding Chemical Space**. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	5
657	Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays. <i>Nucleic Acid Therapeutics</i> , 2023, 33, 132-140.	2.0	1
658	Molecular elements: novel approaches for molecular building. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2023, 378, .	1.8	2
659	YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. <i>Nature Immunology</i> , 2023, 24, 255-266.	7.0	31
660	Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells. <i>Pharmaceutical Research</i> , 2023, 40, 3-25.	1.7	11
661	Molecular dynamics and Raman optical activity spectra reveal nucleotide conformation ratios in solution. <i>Physical Chemistry Chemical Physics</i> , 2023, 25, 8198-8208.	1.3	6
662	Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents. , 2023, , 1-41.		0
663	Efficient Targeted Delivery of Bifunctional Circular Aptamerâ€ASO Chimera to Suppress the SARSâ€CoVâ€2 Proliferation and Inflammation. <i>Small</i> , 2023, 19, .	5.2	3
664	Trace analysis of dimethoxytrityl alcohol (DMT-OH) in oligonucleotide matrices using liquid chromatography coupled with tandem mass spectrometry. <i>Analytical Methods</i> , 0, , .	1.3	0
665	Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2697.	1.8	8

#	ARTICLE	IF	CITATIONS
666	An Antisense Oligonucleotide-Loaded Blood-Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson's Disease. <i>ACS Nano</i> , 2023, 17, 4414-4432.	7.3	10
667	Trioleyl Pyridinium, a Cationic Transfection Agent for the Lipofection of Therapeutic Oligonucleotides into Mammalian Cells. <i>Pharmaceutics</i> , 2023, 15, 420.	2.0	2
668	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
669	Inhibition of SARS-CoV-2 nucleocapsid protein-RNA interaction by guanosine oligomeric RNA. <i>Journal of Biochemistry</i> , 2023, 173, 447-457.	0.9	1
670	Development of a unified gradient theory for ion-pair chromatography using oligonucleotide separations as a model case. <i>Journal of Chromatography A</i> , 2023, 1691, 463823.	1.8	5
671	The Regioselective Conjugation of the 15-nt Thrombin Aptamer with an Optimized Tripeptide Sequence Greatly Increases the Anticoagulant Activity of the Aptamer. <i>Pharmaceutics</i> , 2023, 15, 604.	2.0	1
672	Assessment of immunostimulatory responses to the antimicroRNA-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
673	Exploring the use of the desirability function to optimize the separation of oligonucleotide impurities by ion pair-RP LCMS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2023, 1220, 123666.	1.2	0
674	Nanomedicine is more than a supporting role in rheumatoid arthritis therapy. <i>Journal of Controlled Release</i> , 2023, 356, 142-161.	4.8	7
675	Extracellular vesicles as next generation immunotherapeutics. <i>Seminars in Cancer Biology</i> , 2023, 90, 73-100.	4.3	16
676	Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. <i>Journal of Controlled Release</i> , 2023, 357, 67-83.	4.8	13
677	A proinflammatory long noncoding RNA Lncnc1 regulates inflammasome activation in macrophage. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2023, 324, L584-L595.	1.3	2
678	The mechanism of thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotides. <i>Toxicology in Vitro</i> , 2023, 89, 105569.	1.1	1
679	Self-transfecting GMO-PMO chimera targeting Nanog enable gene silencing in vitro and suppresses tumor growth in 4T1 allografts in mouse. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 32, 203-228.	2.3	4
680	Separation of therapeutic oligonucleotides using ion-pair reversed-phase chromatography based on fundamental separation science. <i>Journal of Chromatography Open</i> , 2023, 3, 100079.	0.8	9
681	Surfactant like peptides for targeted gene delivery to cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2023, 652, 35-45.	1.0	1
682	Convergent Biocatalytic Mediated Synthesis of siRNA. <i>ACS Chemical Biology</i> , 2023, 18, 2183-2187.	1.6	2
683	The Current Status of Antisense Gene Therapies for Bacteria-caused Diseases Challenges and Opportunities. <i>Current Pharmaceutical Design</i> , 2023, 29, 272-282.	0.9	0

#	ARTICLE	IF	CITATIONS
684	Hierarchy of hybrid materials. Part-II: The place of organics-on-inorganics in it, their composition and applications. <i>Frontiers in Chemistry</i> , 0, 11, .	1.8	6
685	Supramolecular Polyphenolâ€DNA Microparticles for In Vivo Adjuvant and Antigen Coâ€Delivery and Immune Stimulation. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	11
686	Supramolecular Polyphenolâ€DNA Microparticles for In Vivo Adjuvant and Antigen Coâ€Delivery and Immune Stimulation. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	3
687	Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery. <i>Developmental Cell</i> , 2023, 58, 174-191.e8.	3.1	12
688	Acyclic (<i>S</i>)-glycol nucleic acid (<i>S</i>-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency. <i>Rna</i> , 2023, 29, 402-414.	1.6	9
689	Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. <i>Nucleic Acids Research</i> , 2023, 51, 1583-1599.	6.5	3
690	Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0281281.	1.1	4
691	Cerium-Doped Self-Assembling Nanoparticles as a Novel Anti-Oxidant Delivery System Preserving Mitochondrial Function in Cortical Neurons Exposed to Ischemia-like Conditions. <i>Antioxidants</i> , 2023, 12, 358.	2.2	4
692	Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. <i>Nucleic Acid Therapeutics</i> , 2023, 33, 83-94.	2.0	17
693	Surface design of nanocarriers: Key to more efficient oral drug delivery systems. <i>Advances in Colloid and Interface Science</i> , 2023, 313, 102848.	7.0	23
694	Systemic Cytokines in Retinopathy of Prematurity. <i>Journal of Personalized Medicine</i> , 2023, 13, 291.	1.1	5
695	Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	6
696	A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future. <i>Pharmaceutics</i> , 2023, 15, 600.	2.0	12
697	Synthesis of multivalent fatty acid-conjugated antisense oligonucleotides: Cell internalization, physical properties, and in vitro and in vivo activities. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 81, 117192.	1.4	1
698	Effects of combinations of gapmer antisense oligonucleotides on the target reduction. <i>Molecular Biology Reports</i> , 2023, 50, 3539-3546.	1.0	0
699	The ULK3 kinase is a determinant of keratinocyte self-renewal and tumorigenesis targeting the arginine methylome. <i>Nature Communications</i> , 2023, 14, .	5.8	4
700	Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	6
701	MÃ©canismes dâ€™action et brevetabilitÃ© des oligonuclÃ©otides thÃ©rapeutiques. <i>Medecine/Sciences</i> , 2023, 39, 111-118.	0,0	0

#	ARTICLE	IF	CITATIONS
702	Orally administered BZL-sRNA-20 oligonucleotide targeting TLR4 effectively ameliorates acute lung injury in mice. <i>Science China Life Sciences</i> , 2023, 66, 1589-1599.	2.3	5
704	Whole-genome sequence of <i>Macaca fascicularis</i> : liver tissue. <i>BMC Genomic Data</i> , 2023, 24, .	0.7	0
705	miRNA as Drug: Antagomir and Beyond. <i>Current Pharmaceutical Design</i> , 2023, 29, 462-465.	0.9	2
706	Post-transcriptional gene silencing by nucleic acid gapmers: a promising therapeutic modality for cancer. <i>Epigenomics</i> , 2023, 15, 53-56.	1.0	0
707	The emerging role of nanotechnology in plant genetic engineering. , 2023, 1, 314-328.		11
708	Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model. <i>Cells</i> , 2023, 12, 702.	1.8	1
709	Polybutylene terephthalate-based stationary phase for ion-pair-free reversed-phase liquid chromatography of small interfering RNA. Part 1: Direct coupling with mass spectrometry. <i>Journal of Chromatography A</i> , 2023, 1694, 463898.	1.8	4
710	Active Nuclear Import of Mammalian Cell-Expressible DNA Origami. <i>Journal of the American Chemical Society</i> , 2023, 145, 4946-4950.	6.6	14
711	Development of a selection assay for small guide RNAs that drive efficient site-directed RNA editing. <i>Nucleic Acids Research</i> , 0, , .	6.5	3
712	Current Status of Oligonucleotide-Based Protein Degraders. <i>Pharmaceutics</i> , 2023, 15, 765.	2.0	2
713	Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and saRNA future therapies. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	0
714	Nucleic Acid Pharmaceutical Agents. , 2023, , 231-268.		0
715	Designing supramolecular self-assembly nanomaterials as stimuli-responsive drug delivery platforms for cancer therapy. <i>IScience</i> , 2023, 26, 106279.	1.9	4
716	â€œIntercellular Mass Transportâ€•Mimic Enables ASO Entry Completely into the Cell Nucleus for Enhanced Ischemia Therapy. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 12777-12786.	4.0	2
717	Geneâ€•targeted therapies: Overview and implications. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2023, 193, 13-18.	0.7	1
718	Proteinâ€•RNA interactions: from mass spectrometry to drug discovery. <i>Essays in Biochemistry</i> , 2023, 67, 175-186.	2.1	1
719	Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery. , 2023, 1, 100005.		4
720	Oligonucleotide Formulations Prepared by High-Speed Electrospinning: Maximizing Loading and Exploring Downstream Processability. <i>Pharmaceutics</i> , 2023, 15, 855.	2.0	1

#	ARTICLE	IF	CITATIONS
721	Ligand-binding assays vs chromatographic platforms for oligonucleotide quantification. <i>Bioanalysis</i> , 2023, 15, 53-55.	0.6	0
722	Chemistry, structure and function of approved oligonucleotide therapeutics. <i>Nucleic Acids Research</i> , 2023, 51, 2529-2573.	6.5	110
723	A red light-triggered chemical tool for sequence-specific alkylation of G-quadruplex and I-motif DNA. <i>Nucleic Acids Research</i> , 2023, 51, 4112-4125.	6.5	5
724	Advanced Therapies for Patients with COVID-19. , 2023, , 77-92.		0
725	Research progress on non-protein-targeted drugs for cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	4
726	Drug discovery processes: When and where the rubber meets the road. , 2023, , 339-415.		1
727	Aptamer-Based Targeted Protein Degradation. <i>ACS Nano</i> , 2023, 17, 6150-6164.	7.3	17
729	Diabetic Polyneuropathy: New Strategies to Target Sensory Neurons in Dorsal Root Ganglia. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5977.	1.8	4
730	Oral administration of the herbal oligonucleotide XKC-sRNA-h3 prevents angiotensin II-induced hypertension in mice. <i>Science China Life Sciences</i> , 2023, 66, 2370-2379.	2.3	5
731	Recycling of Polymerase Chain Reaction (PCR) Kits. <i>ACS Sustainable Chemistry and Engineering</i> , 2023, 11, 5524-5536.	3.2	3
732	The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6121.	1.8	2
733	Aptamer-Based Targeted Delivery of Functional Nucleic Acids. <i>Journal of the American Chemical Society</i> , 2023, 145, 7677-7691.	6.6	21
734	Nanoarchitectures to Deliver Nucleic Acid Drugs to Disease Sites. <i>ChemNanoMat</i> , 2023, 9, .	1.5	1
735	Current, emerging, and potential therapies for non-alcoholic steatohepatitis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	6
736	Small-Molecule Aptamer for Regulating RNA Functions in Mammalian Cells and Animals. <i>Journal of the American Chemical Society</i> , 2023, 145, 7820-7828.	6.6	7
737	miRNAs overexpression and their role in breast cancer: Implications for cancer therapeutics. <i>Current Drug Targets</i> , 2023, 24, .	1.0	0
739	Accessible light-controlled knockdown of cell-free protein synthesis using phosphorothioate-caged antisense oligonucleotides. <i>Communications Chemistry</i> , 2023, 6, .	2.0	3
740	Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. <i>Pharmaceutics</i> , 2023, 15, 1130.	2.0	11

#	ARTICLE	IF	CITATIONS
741	Nanotechnology-enabled gene delivery for cancer and other genetic diseases. Expert Opinion on Drug Delivery, 2023, 20, 523-540.	2.4	2
742	DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors. Cancers, 2023, 15, 2151.	1.7	4
743	Small RNAs: An expanding world with therapeutic promises. Fundamental Research, 2023, 3, 676-682.	1.6	0
744	Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. Nature Reviews Genetics, 2023, 24, 642-658.	7.7	30
745	An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics. Pharmaceutics, 2023, 15, 1158.	2.0	9
746	Exploring Receptor Binding Affinities and Hepatic Cell Association of N-Acetyl-D-Galactosamine-Modified β -Cyclodextrin-Based Polyrotaxanes for Liver-Targeted Therapies. Biomacromolecules, 2023, 24, 2327-2341.	2.6	2
747	A New Wave of Targeting "Undruggable" Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells, 2023, 12, 1110.	1.8	8
748	Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics, 2023, 33, 193-208.	2.0	3
749	Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma. Science Translational Medicine, 2023, 15, .	5.8	5
752	Potential Novel RNA-Targeting Agents for Effective Lipoprotein(a) Lowering: A Systematic Assessment of the Evidence from Completed and Ongoing Developmental Clinical Trials. Journal of Cardiovascular Pharmacology, 2023, Publish Ahead of Print, .	0.8	2
753	Activatable NIR-Photothermal Lipid Nanoparticles for Improved Messenger RNA Delivery. Angewandte Chemie, 0, , .	1.6	0
754	Activatable NIR-Photothermal Lipid Nanoparticles for Improved Messenger RNA Delivery. Angewandte Chemie - International Edition, 2023, 62, .	7.2	6
755	Factors Influencing ADME properties of therapeutic antisense oligonucleotides: physicochemical characteristics and beyond. Current Drug Metabolism, 2023, 24, .	0.7	1
768	Role of miR-424 in the carcinogenesis. Clinical and Translational Oncology, 2024, 26, 16-38.	1.2	0
774	Autosomal and X-Linked Degenerative Ataxias: From Genetics to Promising Therapeutics. Contemporary Clinical Neuroscience, 2023, , 141-181.	0.3	0
775	Antisense Oligonucleotide Therapy Against SCA3. Contemporary Clinical Neuroscience, 2023, , 417-431.	0.3	0
784	Rational design and combinatorial chemistry of ionizable lipids for RNA delivery. Journal of Materials Chemistry B, 2023, 11, 6527-6539.	2.9	4
793	Drug-Grafted DNA for Cancer Therapy. Journal of Physical Chemistry B, 2023, 127, 5379-5388.	1.2	0

#	ARTICLE	IF	CITATIONS
796	Post-transcriptional checkpoints in autoimmunity. <i>Nature Reviews Rheumatology</i> , 2023, 19, 486-502.	3.5	3
798	Introduction to Synthetic Biology. , 2023, , 1-22.		0
803	Modeling of preparative liquid chromatography. , 2023, , 603-624.		0
805	DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer. <i>Experimental and Molecular Medicine</i> , 2023, 55, 879-885.	3.2	4
809	Evolving Therapeutic Targets. , 2024, , 247-252.e1.		0
811	DNA hydrogels and nanogels for diagnostics, therapeutics, and theragnostics of various cancers. <i>Nanoscale</i> , 2023, 15, 10882-10903.	2.8	6
816	Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases. <i>ACS Omega</i> , 2023, 8, 20234-20250.	1.6	6
821	The hepatobiliary system of the non-human primate. , 2023, , 121-145.		0
825	Emerging roles of tRNA-derived small RNAs in cancer biology. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1293-1304.	3.2	4
832	Editorial: Recent trends and spotlight on nucleotide-based drugs: novel targets, their design, delivery, and clinical potential. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
845	Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents. , 2023, , 543-583.		0
860	Novel epigenetic molecular therapies for imprinting disorders. <i>Molecular Psychiatry</i> , 2023, 28, 3182-3193.	4.1	1
862	Stimuli-Responsive Non-viral Nanoparticles for Gene Delivery. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	1
864	Regulatory miRNAs in cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence. <i>The Enzymes</i> , 2023, , .	0.7	0
866	Therapeutic approaches for Duchenne muscular dystrophy. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 917-934.	21.5	8
869	Establishing stereochemical comparability in phosphorothioate oligonucleotides with nuclease P1 digestion coupled with LCMS analysis. <i>Analyst</i> , The, 2023, 148, 5361-5365.	1.7	0
881	Potential of oligonucleotide- and protein/peptide-based therapeutics in the management of toxicant/stressor-induced diseases. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2024, 397, 1275-1310.	1.4	0
885	Novel therapeutic approaches for motor neuron disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 523-537.	1.0	0

#	ARTICLE	IF	CITATIONS
900	RNA Nanomedicine: Delivery Strategies and Applications. AAPS Journal, 2023, 25, .	2.2	1
910	Biopolymers. , 2024, , 205-221.		0
936	Targeted Therapies for Pancreatic Cancer. , 2023, , 67-95.		0
939	The Next Generation of Drug Delivery: Harnessing the Power of Bacteriophages. Methods in Molecular Biology, 2024, , 279-315.	0.4	1
962	Cell-Penetrating Peptides as Vehicles for Delivery of Therapeutic Nucleic Acids. Mechanisms and Application in Medicine. Biochemistry (Moscow), 2023, 88, 1800-1817.	0.7	0
963	Breaking the mold with RNAâ€™a â€™œRNAissanceâ€™ of life science. Npj Genomic Medicine, 2024, 9, .	1.7	0
974	Pulmonary Delivery of Nucleic Acids. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 93-122.	0.1	0
977	RNA therapeutics history and future perspectives. Progress in Molecular Biology and Translational Science, 2024, , 99-114.	0.9	0
979	RNA therapeutics for disorders of excretory system. Progress in Molecular Biology and Translational Science, 2024, , 245-256.	0.9	0
1000	The Future of Gene Therapy: A Review of In Vivo and Ex Vivo Delivery Methods for Genome Editing-Based Therapies. Molecular Biotechnology, 0, , .	1.3	0
1002	Overview of the Nonclinical Development Strategies and Class Effects of Oligonucleotide-based Therapeutics. , 2024, , 769-790.		0